

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number: 001-34045

## Enovis Corporation

(Exact name of registrant as specified in its charter)

Delaware 54-1887631

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

2711 Centerville Road, Suite 400  
Wilmington, Delaware 19808  
(Address of principal executive offices) (Zip Code)

(302) 252-9160

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                       | Trading Symbol(s) | Name of each exchange on which registered |
|---|-------------------|---|
| Common Stock, par value \$0.001 per share | ENOV              | New York Stock Exchange                   |

Common Stock, par value \$0.001 per share

ENOV

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer

Smaller reporting company  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 1, 2024, there were 55,850,500 shares of the registrant's common stock, par value \$.001 per share, outstanding.

## TABLE OF CONTENTS

|   | Page      |
|---|-----------|
| <b>PART I - FINANCIAL INFORMATION</b>   |           |
| Item 1. Financial Statements  | <u>2</u>  |
| Condensed Consolidated Statements of Operations   | <u>2</u>  |
| Condensed Consolidated Statements of Comprehensive Income (Loss)                              | <u>3</u>  |
| Condensed Consolidated Balance Sheets   | <u>4</u>  |
| Condensed Consolidated Statements of Equity   | <u>5</u>  |
| Condensed Consolidated Statements of Cash Flows   | <u>6</u>  |
| Notes to Condensed Consolidated Financial Statements  | <u>7</u>  |
| Note 1. General   | <u>7</u>  |
| Note 2. Recently Issued Accounting Pronouncements   | <u>7</u>  |
| Note 3. Acquisitions and Investments  | <u>7</u>  |
| Note 4. Revenue   | <u>10</u> |
| Note 5. Net Loss Per Share from Continuing Operations   | <u>11</u> |
| Note 6. Income Taxes  | <u>12</u> |
| Note 7. Equity  | <u>13</u> |
| Note 8. Inventories, Net  | <u>14</u> |
| Note 9. Debt  | <u>14</u> |
| Note 10. Accrued Liabilities  | <u>16</u> |
| Note 11. Financial Instruments and Fair Value Measurements                                    | <u>16</u> |
| Note 12. Commitments and Contingencies  | <u>19</u> |
| Note 13. Segment Information  | <u>20</u> |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>22</u> |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk                            | <u>38</u> |
| Item 4. Controls and Procedures   | <u>40</u> |
| <b>PART II - OTHER INFORMATION</b>  |           |
| Item 1. Legal Proceedings   | <u>41</u> |
| Item 1A. Risk Factors   | <u>41</u> |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds                           | <u>41</u> |
| Item 3. Defaults Upon Senior Securities   | <u>42</u> |
| Item 4. Mine Safety Disclosures   | <u>42</u> |
| Item 5. Other Information   | <u>42</u> |
| Item 6. Exhibits  | <u>43</u> |
| <b>SIGNATURES</b>   | <u>43</u> |

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**ENOVIS CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
Dollars in thousands, except per share amounts  
(Uaudited)

|  | Three Months Ended |               | Six Months Ended |               |
|--|--------------------|---------------|------------------|---------------|
|  | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |
| Net sales  | \$ 525,160         | \$ 428,502    | \$ 1,041,426     | \$ 834,653    |
| Cost of sales  | 236,277            | 180,143       | 454,647          | 351,229       |
| Gross profit   | 288,883            | 248,359       | 586,779          | 483,424       |
| Selling, general and administrative expense  | 264,100            | 207,881       | 519,791          | 415,046       |
| Research and development expense   | 23,479             | 18,918        | 46,856           | 37,111        |
| Amortization of acquired intangibles   | 40,936             | 32,249        | 81,867           | 64,289        |
| Restructuring and other charges  | 4,587              | 3,805         | 17,498           | 6,440         |
| Operating loss   | (44,219)           | (14,494)      | (79,233)         | (39,462)      |
| Interest expense, net  | 16,969             | 4,076         | 36,965           | 9,728         |
| Other (income) expense, net  | (33,836)           | 753           | (9,601)          | 92            |
| Loss from continuing operations before income taxes  | (27,352)           | (19,323)      | (106,597)        | (49,282)      |
| Income tax benefit   | (8,908)            | (4,713)       | (16,312)         | (11,826)      |
| Net loss from continuing operations  | (18,444)           | (14,610)      | (90,285)         | (37,456)      |
| (Loss) income from discontinued operations, net of taxes   | (68)               | 4,797         | (68)             | 4,485         |
| Net loss   | (18,512)           | (9,813)       | (90,353)         | (32,971)      |
| Less: net income attributable to noncontrolling interest from continuing operations - net of taxes | 126                | 182           | 283              | 374           |
| Net loss attributable to Enovis Corporation  | \$ (18,638)        | \$ (9,995)    | \$ (90,636)      | \$ (33,345)   |
| <i>Net income (loss) per share - basic and diluted</i>   |                    |               |                  |               |
| Continuing operations  | \$ (0.34)          | \$ (0.27)     | \$ (1.65)        | \$ (0.70)     |
| Discontinued operations  | \$ —               | \$ 0.09       | \$ —             | \$ 0.08       |
| Consolidated operations  | \$ (0.34)          | \$ (0.18)     | \$ (1.65)        | \$ (0.61)     |

See Notes to Condensed Consolidated Financial Statements.

**ENOVIS CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**  
**Dollars in thousands**  
**(Unaudited)**

|  | Three Months Ended |                   | Six Months Ended    |                    |
|--|--------------------|-------------------|---------------------|--------------------|
|  | June 28, 2024      | June 30, 2023     | June 28, 2024       | June 30, 2023      |
| Net loss   | \$ (18,512)        | \$ (9,813)        | \$ (90,353)         | \$ (32,971)        |
| Other comprehensive income (loss):   |                    |                   |                     |                    |
| Foreign currency translation   | (4,208)            | 11,311            | (69,698)            | 21,895             |
| Unrealized gain (loss) on hedging activities, net of tax expense (benefit) of<br>\$(1,966), \$(1,740), \$5,735 and \$(1,740) | (6,584)            | (5,449)           | 18,207              | (5,449)            |
| Amounts reclassified from Accumulated other comprehensive loss:  |                    |                   |                     |                    |
| Amortization of pension net actuarial gain (loss), net of tax expense (benefit) of<br>\$(7), \$(41), \$(14), and \$(41)      | (33)               | (882)             | (68)                | (882)              |
| Reclassification of hedging gain (loss), net of tax expense (benefit) of \$(158),<br>\$—, \$(100), and \$—                   | (544)              | —                 | (358)               | —                  |
| Other comprehensive income (loss)  | (11,369)           | 4,980             | (51,917)            | 15,564             |
| Comprehensive income (loss)  | (29,881)           | (4,833)           | (142,270)           | (17,407)           |
| Less: comprehensive income (loss) attributable to noncontrolling interest  | 109                | 190               | 215                 | 406                |
| Comprehensive income (loss) attributable to Enovis Corporation   | <u>\$ (29,990)</u> | <u>\$ (5,023)</u> | <u>\$ (142,485)</u> | <u>\$ (17,813)</u> |

See Notes to Condensed Consolidated Financial Statements.

**ENOVIS CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**Dollars in thousands, except share amounts**  
**(Unaudited)**

|   | <u>June 28, 2024</u> | <u>December 31, 2023</u> |
|---|----------------------|--------------------------|
| <b>ASSETS</b>   |                      |                          |
| <b>CURRENT ASSETS:</b>  |                      |                          |
| Cash and cash equivalents   | \$ 35,004            | \$ 36,191                |
| Trade receivables, less allowance for credit losses of \$14,853 and \$9,731   | 394,736              | 291,483                  |
| Inventories, net  | 615,037              | 468,832                  |
| Prepaid expenses  | 40,550               | 28,901                   |
| Other current assets  | 87,426               | 71,112                   |
| Total current assets  | 1,172,753            | 896,519                  |
| Property, plant and equipment, net  | 378,449              | 270,798                  |
| Goodwill  | 2,353,456            | 2,060,893                |
| Intangible assets, net  | 1,380,478            | 1,127,363                |
| Lease asset - right of use  | 68,243               | 63,506                   |
| Other assets  | 88,649               | 90,255                   |
| <b>Total assets</b>   | <b>\$ 5,442,028</b>  | <b>\$ 4,509,334</b>      |
| <b>LIABILITIES AND EQUITY</b>   |                      |                          |
| <b>CURRENT LIABILITIES:</b>   |                      |                          |
| Current portion of long-term debt   | \$ 15,028            | \$ —                     |
| Accounts payable  | 159,832              | 132,475                  |
| Accrued liabilities   | 343,145              | 237,132                  |
| Total current liabilities   | 518,005              | 369,607                  |
| Long-term debt, less current portion  | 1,329,427            | 466,164                  |
| Non-current lease liability   | 50,455               | 48,684                   |
| Other liabilities   | 255,203              | 204,178                  |
| <b>Total liabilities</b>  | <b>2,153,090</b>     | <b>1,088,633</b>         |
| <b>Equity:</b>  |                      |                          |
| Common stock, \$0.001 par value; 133,333,333 shares authorized; 54,866,360 and 54,597,142 shares issued and outstanding as of June 28, 2024 and December 31, 2023, respectively | 55                   | 55                       |
| Additional paid-in capital  | 2,911,254            | 2,900,747                |
| Retained earnings   | 451,835              | 542,471                  |
| Accumulated other comprehensive loss  | (76,730)             | (24,881)                 |
| <b>Total Enovis Corporation equity</b>  | <b>3,286,414</b>     | <b>3,418,392</b>         |
| Noncontrolling interest   | 2,524                | 2,309                    |
| <b>Total equity</b>   | <b>3,288,938</b>     | <b>3,420,701</b>         |
| <b>Total liabilities and equity</b>   | <b>\$ 5,442,028</b>  | <b>\$ 4,509,334</b>      |

See Notes to Condensed Consolidated Financial Statements.

**ENOVIS CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY**  
**Dollars in thousands, except share amounts**  
**(Unaudited)**

|  | Common Stock |        | Additional<br>Paid-In Capital | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive Loss | Noncontrolling<br>Interest | Total        |
|--|--------------|--------|-------------------------------|----------------------|--|----------------------------|--------------|
|  | Shares       | Amount |                               |                      |  |                            |              |
| Balance at December 31, 2023                       | 54,597,142   | \$ 55  | \$ 2,900,747                  | \$ 542,471           | \$ (24,881)                                | \$ 2,309                   | \$ 3,420,701 |
| Net income (loss)                                  | —            | —      | —                             | (71,998)             | —  | 157                        | (71,841)     |
| Other comprehensive loss, net of tax of \$7,752    | —            | —      | —                             | —                    | (40,497)                                   | (51)                       | (40,548)     |
| Payments of tax withholding for stock-based awards | —            | —      | (4,772)                       | —                    | —  | —                          | (4,772)      |
| Common stock-based award activity                  | 243,439      | —      | 7,302                         | —                    | —  | —                          | 7,302        |
| Balance at March 29, 2024                          | 54,840,581   | 55     | 2,903,277                     | 470,473              | (65,378)                                   | 2,415                      | 3,310,842    |
| Net income (loss)                                  | —            | —      | —                             | (18,638)             | —  | 126                        | (18,512)     |
| Other comprehensive loss, net of tax of \$(2,131)  | —            | —      | —                             | —                    | (11,352)                                   | (17)                       | (11,369)     |
| Common stock-based award activity                  | 25,779       | —      | 7,977                         | —                    | —  | —                          | 7,977        |
| Balance at June 29, 2024                           | 54,866,360   | \$ 55  | \$ 2,911,254                  | \$ 451,835           | \$ (76,730)                                | \$ 2,524                   | \$ 3,288,938 |

|   | Common Stock |        | Additional<br>Paid-In Capital | Retained<br>Earnings | Accumulated<br>Other<br>Comprehensive Loss | Noncontrolling<br>Interest | Total        |
|---|--------------|--------|-------------------------------|----------------------|--|----------------------------|--------------|
|   | Shares       | Amount |                               |                      |  |                            |              |
| Balance at December 31, 2022                        | 54,228,619   | \$ 54  | \$ 2,925,729                  | \$ 575,732           | \$ (53,430)                                | \$ 1,716                   | \$ 3,449,801 |
| Net income (loss)                                   | —            | —      | —                             | (23,350)             | —  | 192                        | (23,158)     |
| Other comprehensive income, net of tax of \$—       | —            | —      | —                             | —                    | 10,560                                     | 24                         | 10,584       |
| Common stock-based award activity                   | 264,535      | —      | 8,044                         | —                    | —  | —                          | 8,044        |
| Balance at March 31, 2023                           | 54,493,154   | 54     | 2,933,773                     | 552,382              | (42,870)                                   | 1,932                      | 3,445,271    |
| Net income (loss)                                   | —            | —      | —                             | (9,995)              | —  | 182                        | (9,813)      |
| Other comprehensive income, net of tax of \$(1,781) | —            | —      | —                             | —                    | 4,972                                      | 8                          | 4,980        |
| Common stock-based award activity                   | 40,957       | 1      | 10,321                        | —                    | —  | —                          | 10,322       |
| Balance at June 30, 2023                            | 54,534,111   | \$ 55  | \$ 2,944,094                  | \$ 542,387           | \$ (37,898)                                | \$ 2,122                   | \$ 3,450,760 |

See Notes to Condensed Consolidated Financial Statements.

**ENOVIS CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**Dollars in thousands**  
**(Unaudited)**

|   | <b>Six Months Ended</b> |                      |
|---|-------------------------|----------------------|
|   | <b>June 28, 2024</b>    | <b>June 30, 2023</b> |
| <b>Cash flows from operating activities:</b>  |                         |                      |
| Net loss  | \$ (90,353)             | \$ (32,971)          |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |                         |                      |
| Depreciation and amortization   | 139,167                 | 105,033              |
| Impairment of assets  | 5,555                   | —                    |
| Stock-based compensation expense  | 14,102                  | 16,981               |
| Non-cash interest expense   | 2,558                   | 1,481                |
| Fair value gain on contingent acquisition shares  | (20,068)                | —                    |
| Loss on currency hedges   | 11,123                  | —                    |
| Deferred income tax expense (benefit)   | (19,412)                | (107)                |
| Loss on sale of property, plant and equipment   | 383                     | 533                  |
| Changes in operating assets and liabilities:  |                         |                      |
| Trade receivables, net  | (24,807)                | (25,912)             |
| Inventories, net  | 1,953                   | (10,476)             |
| Accounts payable  | (6,744)                 | 8,324                |
| Other operating assets and liabilities  | (41,840)                | (27,326)             |
| <b>Net cash provided by (used in) operating activities</b>                                | <b>(28,383)</b>         | <b>35,560</b>        |
| <b>Cash flows from investing activities:</b>  |                         |                      |
| Purchases of property, plant and equipment and intangibles                                | (76,333)                | (67,248)             |
| Payments for acquisitions, net of cash received, and investments                          | (758,190)               | (98,740)             |
| Payment for settlement of derivatives   | (4,645)                 | —                    |
| <b>Net cash used in investing activities</b>  | <b>(839,168)</b>        | <b>(165,988)</b>     |
| <b>Cash flows from financing activities:</b>  |                         |                      |
| Proceeds from borrowings on term credit facility  | 400,000                 | —                    |
| Repayments of borrowings under term credit facility                                       | (15,000)                | (219,468)            |
| Proceeds from borrowings on revolving credit facilities and other                         | 940,000                 | 370,000              |
| Repayments of borrowings on revolving credit facilities and other                         | (446,479)               | (11,538)             |
| Payment of debt issuance costs  | (703)                   | —                    |
| Payments of tax withholding for stock-based awards  | (4,772)                 | —                    |
| Proceeds from issuance of common stock, net   | 1,177                   | 1,385                |
| Deferred consideration payments and other   | (7,174)                 | (1,668)              |
| <b>Net cash provided by financing activities</b>  | <b>867,049</b>          | <b>138,711</b>       |
| <b>Effect of foreign exchange rates on Cash and cash equivalents</b>                      |                         |                      |
| Increase (decrease) in Cash, cash equivalents and restricted cash                         | (1,408)                 | 8,196                |
| Cash, cash equivalents and restricted cash, beginning of period                           | 44,832                  | 24,295               |
| <b>Cash, cash equivalents and restricted cash, end of period</b>                          | <b>\$ 43,424</b>        | <b>\$ 32,491</b>     |
| <b>Supplemental disclosures - Non-cash investing activities:</b>                          |                         |                      |
| Fair value of contingently issuable shares in business acquisition                        | \$ 107,877              | \$ —                 |

See Notes to Condensed Consolidated Financial Statements.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. General**

Enovis Corporation (the "Company" or "Enovis") is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The Company conducts its business through two operating segments, Prevention & Recovery ("P&R") and Reconstructive ("Recon"). The P&R segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Recon segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools.

The Condensed Consolidated Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States of America ("GAAP") for interim financial statements and reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company's financial position and results of operations as of and for the periods indicated. The Condensed Consolidated Balance Sheet as of December 31, 2023 is derived from the Company's audited financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC's rules and regulations for interim financial statements. The Condensed Consolidated Financial Statements included herein should be read in conjunction with the audited financial statements and related footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), filed with the SEC on February 22, 2024.

The Company makes certain estimates and assumptions in preparing its Condensed Consolidated Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Condensed Consolidated Financial Statements, and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.

**2. Recently Issued Accounting Pronouncements**

The Company has not adopted any new accounting standards during the six months ended June 28, 2024. There are no recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

**3. Acquisitions and Investments**

*Lima Acquisition in 2024*

On January 3, 2024, the Company acquired LimaCorporate S.p.A. ("Lima"), a privately held global orthopedic company, at an enterprise value of € 800 million (the "Lima Acquisition"), consisting of (i) approximately €700 million in cash consideration, which includes the repayment at closing of certain indebtedness of Lima and (ii) 1,942,686 shares of common stock of Enovis, par value \$ 0.001 per share (the "Contingent Acquisition Shares"), which is based upon a €100 million value divided by the thirty-day volume weighted average price of Enovis common stock as of the close of business on September 21, 2023. The Contingent Acquisition Shares are expected to be issued in two equal tranches within six and twelve months of the acquisition date upon non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The cash paid for acquisition was \$758.6 million, net of acquired cash. The fair value of the Contingent Acquisition Shares at closing was \$ 107.9 million based on the Enovis share price at the close of business on January 3, 2024. The Contingent Acquisition Shares liability, recorded in Accrued liabilities, will be adjusted to fair value each reporting period with the adjustment reflected in Other income (expense), net in the Condensed Consolidated Statement of Operations. Subsequent to the end of the second quarter of 2024, the first tranche of the Contingent Acquisition Shares of 971,343 shares were issued to the seller on July 16, 2024.

Lima operates in the reconstructive space of patient care, providing tailored hardware and digital innovation to advance a global standard of care and positive patient outcomes. Lima has approximately 1,000 employees across more than 15 locations around the world. The acquisition extends the Company's current footprint to emerging and growing markets, expands its product lines, and strengthens its global innovation platform. The value included as Goodwill for this acquisition is reflective of these expected benefits in conjunction with anticipated synergies as the Company uses its integration experience effectively to

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

drive further operating improvement, margin expansion, and long-term growth. Enovis uses its experience and EGX business management system, a comprehensive set of tools and repeatable, teachable processes, to integrate acquisitions and create superior value for its customers, shareholders and associates.

The Company incurred \$9.7 million of advisory, legal, audit, valuation and other professional service fees in connection with the Lima Acquisition in the first quarter of 2024, which are included in Selling, general and administrative expense in the Condensed Consolidated Statement of Operations.

The Lima Acquisition was accounted for as a business combination using the acquisition method of accounting and accordingly, the Condensed Consolidated Financial Statements include the financial position and results of operations from the date of acquisition. The following unaudited proforma financial information presents Enovis's consolidated financial information assuming the acquisition had taken place on January 1, 2023. These amounts are presented in accordance with GAAP, consistent with the Company's accounting policies.

|   | Three Months Ended |               | Six Months Ended |               |
|---|--------------------|---------------|------------------|---------------|
|   | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |
|   | (In thousands)     |               |                  |               |
| Net Sales   | \$ 525,160         | \$ 502,547    | \$ 1,041,426     | \$ 986,690    |
| Net loss from continuing operations attributable to<br>Enovis | (45,184)           | (55,205)      | (87,425)         | (100,185)     |

The following table summarizes the Company's provisional estimate of the aggregate fair value of the assets acquired and liabilities assumed at the date of acquisition. These amounts, including inventories, deferred taxes, intangible assets, useful lives of the intangible assets, and property, plant and equipment, are determined based upon certain valuations and studies that have yet to be finalized. Accordingly, the assets acquired and liabilities assumed, as detailed below, are subject to adjustment once the detailed analyses are completed, which could be material. Substantially all of the Goodwill recognized is not expected to be deductible for income tax purposes.

|   | January 3, 2024 |  |
|---|-----------------|--|
|   | (In thousands)  |  |
| Trade receivables                                       | \$ 87,222       |  |
| Inventories   | 157,219         |  |
| Property, plant and equipment                           | 110,279         |  |
| Goodwill  | 323,617         |  |
| Intangible assets                                       | 348,000         |  |
| Accounts payable  | (37,043)        |  |
| Accrued liabilities                                     | (54,660)        |  |
| Other assets and liabilities, net                       | (68,126)        |  |
| Total fair value of consideration, net of acquired cash | 866,508         |  |
| Less: fair value of Contingent Acquisition Shares       | (107,877)       |  |
| Acquisition consideration paid, net of acquired cash    | \$ 758,631      |  |

The following summarizes the preliminary values of the Intangible assets acquired, excluding Goodwill, as of June 28, 2024:

|                         | Intangible Asset         | Weighted Average    |    |
|-------------------------|--------------------------|---------------------|----|
|                         |                          | Amortization Period |    |
|                         | (In thousands)           | (Years)             |    |
| Trademarks              | \$ 51,000                |                     | 20 |
| Customer Relationships  | 111,000                  |                     | 15 |
| Acquired technology     | 186,000                  |                     | 15 |
| Total Intangible Assets | <u><u>\$ 348,000</u></u> |                     |    |

During the three and six months ended June 28, 2024, the Company's Condensed Consolidated Statements of Operations included \$ 83.5 million and \$169.3 million, of net sales and \$15.6 million and \$12.0 million of net loss, respectively, associated with the acquired Lima legal entities.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

**2023 Acquisitions**

On June 28, 2023, the Company completed the acquisition of Novastep SAS ("Novastep") in its Recon segment. Novastep is a leading player in Minimally Invasive Surgery (MIS) foot and ankle solutions with a best-in-class MIS bunion system serving a rapidly growing portion of the global bunion segment. The acquisition is accounted for as a business combination using the acquisition method of accounting, and accordingly, the Consolidated Financial Statements include the financial position and results of operations from the acquisition date. The Company paid \$96.9 million for the acquisition, net of cash received. The Company allocated \$43.7 million to goodwill and \$52.0 million to intangible assets acquired. The purchase accounting related to the Novastep acquisition has been completed. The acquired goodwill value is primarily driven by the expected synergies from cross-selling Novastep products to existing Enovis foot & ankle customers. The acquisition broadens our reconstructive product offerings for the foot and ankle market and expands our customer base in Europe.

On July 20, 2023, the Company completed an asset acquisition transaction with D.N.E., LLC ("DNE") in its Recon segment. DNE is a developer of a broad line of external fixation products, including circular frames, pin-to-bar frames, and mini-fixators for use in foot and ankle surgeries. The acquisition of these assets, primarily the developed technology will allow Enovis to expand its robust product portfolio for the Foot & Ankle business unit. The Company paid \$28.2 million for the asset acquisition and assigned \$25.8 million to intangible assets, \$1.9 million to finished goods inventory and \$0.5 million to property, plant and equipment. The Condensed Consolidated Financial Statements include the financial position and results of operations from the acquisition date.

On October 5, 2023, the Company acquired a 100% interest in Precision AI Pty Ltd ("Precision AI"), a developer of surgical planning software. The transaction was accounted for as an asset acquisition. The acquisition complements the Company's current product offerings in its Recon segment with advanced planning software for shoulder surgery and opportunity to expand to additional anatomies. On the acquisition date, the Company paid \$17.6 million, net of cash received and agreed to make contingent payments of approximately \$12.0 million upon the successful completion of three milestones within one year of the acquisition date. The milestones are based on FDA approvals and user validation testing of the software.

In December 2023, the first milestone was achieved and the Company paid \$4.2 million to the seller. The remaining contingent amount is held in escrow by Enovis as restricted cash and presented in Other current assets in the Condensed Consolidated Balance Sheet. The Company has control over these funds and is required to authorize the transfer upon completion of the milestones. The potential additional contingent payments are not recorded until the milestones are achieved. The Condensed Consolidated Financial Statements include the assets acquired and results of operations from the acquisition date.

**Restricted Cash**

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are excluded from Cash and cash equivalents in the Condensed Consolidated Balance Sheets. Restricted cash is recorded as a component of Other current assets on the Condensed Consolidated Balance Sheets. The balance in restricted cash as of June 28, 2024 and December 31, 2023 is related to the acquisition of Precision AI which closed in the fourth quarter of 2023 and will be released to the seller within one year of the acquisition date upon completion of certain milestones.

The following table summarizes the Company's cash, cash equivalents and restricted cash:

|  | <b>June 28, 2024</b> | <b>December 31, 2023</b> |
|--|----------------------|--------------------------|
|  | (In thousands)       |                          |
| Cash and cash equivalents                                  | \$ 35,004            | \$ 36,191                |
| Restricted cash  | 8,420                | 8,641                    |
| <b>Total cash and cash equivalents and restricted cash</b> | <b>\$ 43,424</b>     | <b>\$ 44,832</b>         |

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

*Investments*

As of June 28, 2024, the balance of investments held by the Company without readily determinable fair values was \$ 20.4 million. The majority of these investments are carried at cost less impairments, if any, plus adjustments for fair value indicators from observable price changes in orderly transactions for the identical or similar investment of the same issuer. There have been no impairments or upward adjustments in the current year or since acquisition of these investments. One investment is accounted for under the equity method of accounting and is recorded at the initial investment amount, adjusted each period for the Company's share of the income or loss.

**4. Revenue**

The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company's sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company's revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic/product type groups within its segments:

|  | Three Months Ended |                   | Six Months Ended    |                   |
|--|--------------------|-------------------|---------------------|-------------------|
|  | June 28, 2024      | June 30, 2023     | June 28, 2024       | June 30, 2023     |
|  | (In thousands)     |                   |                     |                   |
| <b>Prevention &amp; Recovery:</b>      |                    |                   |                     |                   |
| U.S. Bracing & Support                 | \$ 117,537         | \$ 114,963        | \$ 222,111          | \$ 219,338        |
| U.S. Other P&R                         | 67,950             | 67,729            | 134,300             | 130,076           |
| International P&R                      | 92,267             | 90,783            | 180,356             | 174,801           |
| <b>Total Prevention &amp; Recovery</b> | <b>277,754</b>     | <b>273,475</b>    | <b>536,767</b>      | <b>524,215</b>    |
| <b>Reconstructive:</b>                 |                    |                   |                     |                   |
| U.S. Recon                             | 122,062            | 106,146           | 245,797             | 209,638           |
| International Recon                    | 125,344            | 48,881            | 258,862             | 100,800           |
| <b>Total Reconstructive</b>            | <b>247,406</b>     | <b>155,027</b>    | <b>504,659</b>      | <b>310,438</b>    |
| <b>Total</b>                           | <b>\$ 525,160</b>  | <b>\$ 428,502</b> | <b>\$ 1,041,426</b> | <b>\$ 834,653</b> |

Given the nature of its businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year.

The nature of the Company's contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue.

*Allowance for Credit Losses*

The Company's estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model considers current conditions and reasonable and supportable forecasts for current and projected macroeconomic factors.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

A summary of the activity in the Company's allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:

|                             | Six Months Ended June 28, 2024       |                            |                                |                                       |                                    |                                | (In thousands) |
|-----------------------------|--------------------------------------|----------------------------|--------------------------------|---------------------------------------|------------------------------------|--------------------------------|----------------|
|                             | Balance at<br>Beginning<br>of Period | Charged to<br>Expense, net | Write-Offs,<br>Deductions, net | Other Activity,<br>net <sup>(1)</sup> | Foreign<br>Currency<br>Translation | Balance at<br>End of<br>Period |                |
|                             |                                      |                            |                                |                                       |                                    |                                |                |
| Allowance for Credit Losses | \$ 9,731                             | \$ 3,374                   | \$ (1,471)                     | \$ 3,417                              | \$ (198)                           | \$ 14,855                      |                |

<sup>(1)</sup> Represents fair value adjustments related to acquisitions

## 5. Net Income (Loss) Per Share from Continuing Operations

Net income (loss) per share from continuing operations was computed using the treasury stock method as follows:

|  | Three Months Ended |               | Six Months Ended |               |
|--|--------------------|---------------|------------------|---------------|
|  | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |

(In thousands, except share and per share data)

### Computation of Net income (loss) per share from continuing operations - basic:

|  |             |             |             |             |
|--|-------------|-------------|-------------|-------------|
| Net income (loss) from continuing operations attributable to Enovis Corporation <sup>(1)</sup> | \$ (18,570) | \$ (14,792) | \$ (90,568) | \$ (37,830) |
| Weighted-average shares of Common stock outstanding – basic                                    | 54,855,810  | 54,510,688  | 54,772,231  | 54,418,554  |
| Net income (loss) per share from continuing operations – basic                                 | \$ (0.34)   | \$ (0.27)   | \$ (1.65)   | \$ (0.70)   |

### Computation of Net income (loss) per share from continuing operations - diluted:

|  |             |             |             |             |
|--|-------------|-------------|-------------|-------------|
| Net income (loss) from continuing operations attributable to Enovis Corporation <sup>(1)</sup> | \$ (18,570) | \$ (14,792) | \$ (90,568) | \$ (37,830) |
| Weighted-average shares of Common stock outstanding – basic                                    | 54,855,810  | 54,510,688  | 54,772,231  | 54,418,554  |
| Net effect of potentially dilutive securities - stock options and restricted stock units       | —           | —           | —           | —           |
| Weighted-average shares of Common stock outstanding – diluted                                  | 54,855,810  | 54,510,688  | 54,772,231  | 54,418,554  |
| Net income (loss) per share from continuing operations – diluted                               | \$ (0.34)   | \$ (0.27)   | \$ (1.65)   | \$ (0.70)   |

<sup>(1)</sup> Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes.

The following weighted average computations of potentially dilutive shares of Common stock from stock-based compensation awards were excluded from the calculation of Weighted-average shares of Common stock outstanding – diluted as inclusion would be anti-dilutive in Net income (loss) per share:

|  | Three Months Ended |               | Six Months Ended |               |
|--|--------------------|---------------|------------------|---------------|
|  | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |
| Weighted average computation of potentially dilutive shares of Common stock excluded from diluted computation, as inclusion would be anti-dilutive |                    |               |                  |               |
|  | 1,378,308          | 1,231,504     | 1,106,763        | 1,154,108     |

In conjunction with the Lima Acquisition, the Company agreed to a contingent issuance of 1,942,686 Contingent Acquisition Shares. The Contingent Acquisition Shares are currently expected to be issued within one year from the completion of the Lima Acquisition upon the non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The Contingent Acquisition Shares are only to be included in the weighted-average calculation of basic shares when there are no circumstances the shares would not be issued. The Contingent Acquisition Shares are only to be included in the weighted-average calculation of diluted shares when the conditions are satisfied. As such, the shares have been excluded from the calculation of basic and diluted weighted-average shares, respectively. Subsequent to the end of the second quarter of 2024, the first tranche of the Contingent Acquisition Shares of

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

971,343 shares were issued to the seller on July 16, 2024. The first tranche shares will be incorporated into the weighted-average shares of common stock outstanding — basic in the third quarter of 2024.

**6. Income Taxes**

|   | Three Months Ended |               | Six Months Ended |               |
|---|--------------------|---------------|------------------|---------------|
|   | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |
| (In thousands)                                      |                    |               |                  |               |
| Loss from continuing operations before income taxes | \$ (27,352)        | \$ (19,323)   | \$ (106,597)     | \$ (49,282)   |
| Income tax benefit                                  | \$ (8,908)         | \$ (4,713)    | \$ (16,312)      | \$ (11,826)   |
| Effective tax rate:                                 | 32.6 %             | 24.4 %        | 15.3 %           | 24.0 %        |

The effective tax rate for the three months ended June 28, 2024 was higher than the 2024 federal statutory rate of 21%, primarily due to tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares. This was partially offset by an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations.

The effective tax rate for the six months ended June 28, 2024 was lower than the 2024 federal statutory rate of 21%, primarily due to an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations. This was partially offset by tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares.

The effective tax rate for the three and six months ended June 30, 2023 was higher than the 2023 U.S. federal statutory rate of 21%, primarily due to non-U.S. income being taxed at lower rates, the release of a valuation allowance on non-U.S. attributes, tax credits for research and development, and release of uncertain tax positions. This was partially offset by other non-deductible expenses and the U.S. taxation on international operations.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

**7. Equity**

*Share Repurchase Program*

In 2018, the Company's Board of Directors authorized the repurchase of shares of the Company's Common stock from time-to-time on the open market or in privately negotiated transactions. No repurchases of the Company's Common stock have been made under this plan since the third quarter of 2018. As of June 28, 2024, the remaining stock repurchase authorization provided by the Board of Directors was \$100 million. The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. There is no term associated with the remaining repurchase authorization.

*Accumulated Other Comprehensive Income (Loss)*

The following tables present the changes in the balances of each component of Accumulated other comprehensive income (loss) including reclassifications out of Accumulated other comprehensive loss for the six months ended June 28, 2024 and June 30, 2023. All amounts are presented net of tax and noncontrolling interest, if any.

| <b>Accumulated Other Comprehensive Loss Components</b>                  |   |   |                                    |                    |       |
|---|---|---|------------------------------------|--------------------|-------|
|   | Net Unrecognized<br>Pension Benefit<br>Cost | Foreign Currency<br>Translation<br>Adjustment | (Loss) on<br>Hedging<br>Activities | Unrealized Gain    | Total |
| (In thousands)  |   |   |                                    |                    |       |
| Balance at January 1, 2024  | \$ 5,008                                    | \$ (2,016)                                    | \$ (27,873)                        | \$ (24,881)        |       |
| Other comprehensive income (loss) before reclassifications:             |   |   |                                    |                    |       |
| Foreign currency translation adjustment                                 | (330)                                       | (69,300)                                      | —                                  | (69,630)           |       |
| Gain on hedges  | —   | —   | 18,207                             | 18,207             |       |
| Other comprehensive income (loss) before reclassifications              | (330)                                       | (69,300)                                      | 18,207                             | (51,423)           |       |
| Amounts reclassified from Accumulated other comprehensive income (loss) | (68)  | —   | (358)                              | (426)              |       |
| Net Other comprehensive income (loss)                                   | (398)                                       | (69,300)                                      | 17,849                             | (51,849)           |       |
| Balance at June 28, 2024  | <u>\$ 4,610</u>                             | <u>\$ (71,316)</u>                            | <u>\$ (10,024)</u>                 | <u>\$ (76,730)</u> |       |

| <b>Accumulated Other Comprehensive Loss Components</b>                  |   |   |   |                    |       |
|---|---|---|---|--------------------|-------|
|   | Net Unrecognized<br>Pension Benefit<br>Cost | Foreign Currency<br>Translation<br>Adjustment | Unrealized Loss<br>on Hedging<br>Activities | —                  | Total |
| (In thousands)  |   |   |   |                    |       |
| Balance at January 1, 2023  | \$ 12,207                                   | \$ (65,637)                                   | \$ —  | \$ (53,430)        |       |
| Other comprehensive income (loss) before reclassifications:             |   |   |   |                    |       |
| Foreign currency translation adjustment                                 | 383   | 21,480  | —   | 21,863             |       |
| Loss on net investment hedges   | —   | —   | (5,449)                                     | (5,449)            |       |
| Other comprehensive income (loss) before reclassifications              | 383   | 21,480  | (5,449)                                     | 16,414             |       |
| Amounts reclassified from Accumulated other comprehensive income (loss) | (882)                                       | —   | —   | (882)              |       |
| Net Other comprehensive income (loss)                                   | (499)                                       | 21,480  | (5,449)                                     | 15,532             |       |
| Balance at June 30, 2023  | <u>\$ 11,708</u>                            | <u>\$ (44,157)</u>                            | <u>\$ (5,449)</u>                           | <u>\$ (37,898)</u> |       |

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

**8. Inventories, Net**

Inventories, net consisted of the following:

|  | June 28, 2024  | December 31, 2023 |
|--|----------------|-------------------|
|  | (In thousands) |                   |
| Raw materials  | \$ 103,992     | \$ 88,129         |
| Work in process  | 51,516         | 39,310            |
| Finished goods   | 540,753        | 406,931           |
|  | <hr/>          | <hr/>             |
|  | 696,261        | 534,370           |
| Less: Allowance for excess, slow-moving and obsolete inventory | (81,224)       | (65,538)          |
|  | <hr/>          | <hr/>             |
|  | \$ 615,037     | \$ 468,832        |
|  | <hr/>          | <hr/>             |

**9. Debt**

Long-term debt consisted of the following:

|                                       | June 28, 2024  | December 31, 2023 |
|---------------------------------------|----------------|-------------------|
|                                       | (In thousands) |                   |
| Term loan                             | \$ 381,743     | \$ —              |
| Senior unsecured convertible notes    | 447,592        | 446,164           |
| Revolving credit facilities and other | 515,120        | 20,000            |
|                                       | <hr/>          | <hr/>             |
| Total debt                            | 1,344,455      | 466,164           |
| Less: current portion                 | (15,028)       | —                 |
|                                       | <hr/>          | <hr/>             |
| Long-term debt                        | \$ 1,329,427   | \$ 466,164        |
|                                       | <hr/>          | <hr/>             |

*Term Loan and Revolving Credit Facility*

On April 4, 2022, the Company entered into a credit agreement (the "Enovis Credit Agreement"), consisting of a \$ 900 million revolving credit facility (the "Revolver") with an April 4, 2027 maturity date and an initial term loan in the aggregate principal amount of \$450 million (the "2022 Term Loan") which was fully extinguished during the first quarter of 2023. The Revolver contains a \$50 million swing line loan sub-facility. Certain U.S. subsidiaries of the Company guarantee the obligations under the Enovis Credit Agreement. The agreement was amended on October 23, 2023, in conjunction with the financing of the Lima Acquisition as further discussed below.

The Enovis Credit Agreement, as amended, contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments, or pay dividends. In addition, the Enovis Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum senior secured leverage ratio of not more than 3.75:1.00 stepping down to 3.50:1.00 for the fiscal quarter ending June 30, 2024 and thereafter, and (ii) a minimum interest coverage ratio of 3.00:1.00. The Enovis Credit Agreement contains various events of default (including failure to comply with the covenants under the Enovis Credit Agreement and related agreements), and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Enovis Credit Agreement. As of June 28, 2024, the Company was in compliance with the covenants under the Enovis Credit Agreement.

As of June 28, 2024, the weighted-average interest rate of borrowings under the Enovis Credit Agreement was 7.19% excluding accretion of deferred financing fees, and there was \$385 million available on the Revolver.

*Financing for Lima Acquisition*

On October 23, 2023 the Company entered into an amendment to the Enovis Credit Agreement (the "Amendment"), which provided for a new term loan commitment in the aggregate amount of \$400 million. The term loan facility extended to the Company under the Amendment was funded on January 3, 2024, the date the Lima Acquisition was consummated. The term loan requires quarterly principal repayments at 1.25% of the initial aggregate principal amount, which is \$5 million each quarter, and matures on April 4, 2027 (the "2024 Term Loan").

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

Pursuant to the Amendment, effective as of the date of consummation of the Lima Acquisition, (i) all facilities under the Enovis Credit Agreement (including the 2024 Term Loan) became secured by certain personal property of the Company and certain of its subsidiaries, subject to limitations and exclusions; (ii) the financial covenant under the Enovis Credit Agreement was adjusted to a new senior secured leverage ratio (as disclosed above); (iii) certain changes to the negative covenants became effective (including restrictions on repayments of junior financing and amendments to junior financing documents); and (iv) certain additional changes were implemented (including the removal of the guaranty fallaway provision).

On October 24, 2023, the Company issued \$460 million aggregate principal amount of senior unsecured convertible notes in a private placement pursuant to Rule 144A (the “2028 Notes”). The 2028 Notes have an interest rate of 3.875%, payable semiannually in arrears on April 15 and October 15 of each year, beginning April 15, 2024 and will mature on October 15, 2028 unless earlier repurchased, redeemed, or converted. The effective interest rate on the 2028 Notes is 4.5%. For the six months ended June 28, 2024, the interest expense on the 2028 Notes was \$ 10.1 million, including \$8.7 million based upon the coupon rate and \$1.4 million from accretion of the discount.

Holders may convert their 2028 Notes in multiples of \$1,000 principal amount prior to the close of business April 15, 2028 under the following circumstances: (i) during any calendar quarter commencing after the calendar quarter ending on December 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (ii) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per \$1,000 principal amount of 2028 Notes, as determined following a request by a holder of 2028 Notes in accordance with the procedures described in the 2028 Note indenture, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (iii) if the Company calls any or all of the 2028 Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (iv) upon the occurrence of specified corporate events as described in the indenture governing the 2028 Notes.

In addition, holders may convert their 2028 Notes, in multiples of \$1,000 principal amount, at their option at any time beginning on or after April 15, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, regardless of the foregoing circumstances. The conversion rate is 17.1474 shares of common stock per \$1,000 principal amount of 2028 Notes (equivalent to an initial conversion price of approximately \$58.32 per share of common stock), subject to adjustment upon the occurrence of certain specified events as set forth in the indenture governing the 2028 Notes. Upon conversion, the Company will pay cash up to the aggregate principal amount of the 2028 Notes to be converted and pay or deliver, as the case may be, cash, shares of common stock or a combination of cash and shares of common stock, at its election, in respect of the remainder.

On October 24, 2023, the Company also entered into privately negotiated capped call transactions with certain of the initial purchasers of the 2028 Notes and paid \$62 million to the counterparties. The capped call transactions are intended generally to mitigate potential dilution to the Company’s common stock upon conversion of any Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. If, however, the market price per share of common stock exceeds \$89.72, the initial cap price of the capped call transactions, there would be a dilutive effect and/or no offset of any cash payments, in each case, attributable to the amount by which the market price of the common stock exceeds the cap price. The capped call payment was classified as equity since it meets the derivative scope exception included in Accounting Standards Codification Topic 815 Derivatives and Hedging.

*Other Indebtedness*

In addition to the debt agreements discussed above, the Company is party to overdraft facilities with a borrowing capacity of \$30.0 million. Total letters of credit and surety bonds of \$34.1 million were outstanding as of June 28, 2024.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

**Deferred Financing Fees**

The Company has \$2.9 million in deferred financing fees included in Other assets as of June 28, 2024. As of June 28, 2024, the Company has \$15.7 million of original issue discount fees and other issuance costs included as a reduction of Long-term debt related to the 2024 Term Loan and the 2028 Notes.

**10. Accrued Liabilities**

Accrued liabilities in the Condensed Consolidated Balance Sheets consisted of the following:

|  | <b>June 28, 2024</b>    | <b>December 31, 2023</b> |
|--|-------------------------|--------------------------|
|  | <b>(In thousands)</b>   |                          |
| Contingent consideration - current portion                 | \$ 95,354               | \$ 5,972                 |
| Accrued compensation and related benefits                  | 71,797                  | 70,979                   |
| Accrued third-party commissions                            | 30,686                  | 28,539                   |
| Lease liability - current portion                          | 22,295                  | 21,568                   |
| Accrued taxes  | 16,909                  | 14,384                   |
| Accrued rebates  | 13,769                  | 14,464                   |
| Accrued professional fees                                  | 7,453                   | 13,037                   |
| Accrued royalties  | 6,704                   | 6,944                    |
| Accrued freight  | 5,258                   | 3,909                    |
| Accrued interest   | 4,336                   | 3,765                    |
| Derivative liability – current portion                     | 3,892                   | 278                      |
| Customer advances and billings in excess of costs incurred | 3,479                   | 2,953                    |
| Warranty liability   | 2,960                   | 2,959                    |
| Accrued restructuring liability                            | 2,665                   | 2,276                    |
| Other  | 55,588                  | 45,105                   |
|  | <hr/> <u>\$ 343,145</u> | <hr/> <u>\$ 237,132</u>  |

**Accrued Restructuring Liability**

The Company's restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company's restructuring liability included in Accrued liabilities in the Condensed Consolidated Balance Sheets is as follows:

|   | <b>Six Months Ended June 28, 2024</b>         |                        |                          |                       |   |                                     |  |
|---|---|------------------------|--------------------------|-----------------------|---|-------------------------------------|--|
|   | <b>Balance at<br/>Beginning of<br/>Period</b> |                        |                          |                       | <b>Foreign Currency<br/>Translation</b> | <b>Balance at End<br/>of Period</b> |  |
|   |   | <b>Provisions</b>      | <b>Payments</b>          | <b>(In thousands)</b> |   |                                     |  |
| <b>Restructuring and other charges:</b>         |   |                        |                          |                       |   |                                     |  |
| Termination benefits <sup>(1)</sup>             | \$ 2,195                                      | \$ 6,584               | \$ (6,217)               | \$ 16                 | \$ 2,578                                |                                     |  |
| Facility closure costs and other <sup>(2)</sup> | 81  | 5,359                  | (5,353)                  | —                     | 87                                      |                                     |  |
| Total   | <hr/> <u>\$ 2,276</u>                         | <hr/> <u>11,943</u>    | <hr/> <u>\$ (11,570)</u> | <hr/> <u>\$ 16</u>    | <hr/> <u>\$ 2,665</u>                   |                                     |  |
| Non-cash charges <sup>(2)</sup>                 |   | 5,555                  |                          |                       |   |                                     |  |
| <b>Total Provisions<sup>(3)</sup></b>           |   | <hr/> <u>\$ 17,498</u> |                          |                       |   |                                     |  |

<sup>(1)</sup> Includes severance and other termination benefits, including outplacement services.

<sup>(2)</sup> Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of facilities, site cost structures, and product lines.

<sup>(3)</sup> For the six months ended June 28, 2024, \$0.5 million and \$8.0 million of the Company's total provisions were related to the P&R and Recon segments, respectively. The non-cash charges was an impairment of assets associated with divesting a minor product line in P&R.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

## **11. Financial Instruments and Fair Value Measurements**

The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

**Level One:** Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

**Level Two:** Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

**Level Three:** Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying values of financial instruments, including trade receivables, other receivables and accounts payable, approximate their fair values due to their short-term maturities. The carrying value of the Company's term loan and revolving credit facility debt, which bears a variable interest rate indexed to the Secured Overnight Financing Rate (SOFR), approximates fair value as it reprices when market interest rates change. Based on current interest rates for similar types of borrowings, the estimated fair value of the Company's total debt, including the Senior unsecured convertible notes, the 2024 Term Loan, and the Revolver, was \$1,385.2 million and \$573.2 million as of June 28, 2024 and December 31, 2023, respectively. The estimated fair value, a Level Two valuation in the fair value hierarchy, may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.

As of June 28, 2024, the Company held \$20.5 million in Level Three liabilities arising from contingent consideration related to acquisitions that may settle in cash. The fair value of the contingent consideration liabilities is determined using unobservable inputs and the inputs vary based on the nature of the purchase agreements. These inputs can include the estimated amount and timing of projected cash flows, the risk-adjusted discount rate used to present value the projected cash flows, and the probability of the acquired company attaining certain targets stated within the purchase agreements. A change in these unobservable inputs to a different amount might result in a significantly higher or lower fair value measurement at the reporting date due to the nature of uncertainty inherent to the estimates. During the six months ended June 28, 2024, the Company recorded a net \$5.5 million reduction in contingent consideration primarily due to \$6.3 million in settlements of revenue-based contingent consideration arrangements.

The gross range of outcomes for contingent consideration arrangements that have a fixed limit on the maximum payout is zero to \$7.5 million. There is one contingent consideration arrangement remaining that has no limit and is based on a percentage of sales in excess of a benchmark over a five-year period through 2027.

Additionally, in conjunction with the Lima Acquisition, the Company agreed to a contingent issuance of 1,942,686 Contingent Acquisition Shares, as determined based upon a €100 million value divided by the thirty-day volume weighted average price of Enovis common stock as of the close of business on September 21, 2023. The Contingent Acquisition Shares are expected to be issued in two equal tranches within six and twelve months of the acquisition date upon the non-occurrence of certain future events, in each case subject to certain adjustments and conditions as provided for in the purchase agreement. The initial fair value of the Contingent Acquisition Shares at closing was \$107.9 million based on the Enovis share price at the close of business on January 3, 2024. The Contingent Acquisition Shares liability, recorded in Accrued liabilities, is adjusted to fair value each reporting period with the adjustments reflected in Other income (expense), net in the Condensed Consolidated Statement of Operations. The adjustments were gains of \$33.5 million and \$20.1 million for the three and six months ended June 28, 2024, respectively. The fair value of the Contingent Acquisition Shares liability is Level One in the fair value hierarchy as it is determined using the quoted market prices. Subsequent to the end of the second quarter of 2024, the first tranche of the Contingent Acquisition Shares of 971,343 shares were issued to the seller on July 16, 2024.

There were no transfers in or out of Level One, Two or Three during the six months ended June 28, 2024.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

|  | Total Contingent Consideration Rollforward |                   |                    |             |                   |                  |             | Ending Balance    |
|--|--|-------------------|--------------------|-------------|-------------------|------------------|-------------|-------------------|
|  | Beginning Balance                          | Additions         | Charges / (Gain)   | Interest    | Payments          | Foreign Exchange |             |                   |
|  | (In thousands)                             |                   |                    |             |                   |                  |             |                   |
| Contingent Consideration - Level One   | \$ —                                       | \$ 107,877        | \$ (20,068)        | \$ —        | \$ —              | \$ —             | \$ —        | \$ 87,809         |
| Contingent Consideration - Level Three | 26,025                                     | 1,100             | —                  | —           | (6,281)           | (333)            | —           | 20,511            |
| <b>Total Contingent Consideration</b>  | <b>\$ 26,025</b>                           | <b>\$ 108,977</b> | <b>\$ (20,068)</b> | <b>\$ —</b> | <b>\$ (6,281)</b> | <b>\$ (333)</b>  | <b>\$ —</b> | <b>\$ 108,320</b> |

*Deferred Compensation Plans*

The Company maintains deferred compensation plans for the benefit of certain employees and non-executive officers. As of June 28, 2024 and December 31, 2023 the fair value of these plans were \$16.5 million and \$14.4 million, respectively. These plans are deemed to be Level Two within the fair value hierarchy.

*Forward Currency Contracts*

The Company's objective in using forward currency contracts is to add stability to the Company's earnings and to protect the U.S. Dollar value of forecasted transactions. To accomplish this objective, the Company has entered into forward currency contract agreements between the U.S. Dollar and the Mexican Peso as part of its risk management strategy. These forward currency contract agreements are designated and qualify as cash flow hedges.

The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in Unrealized gain (loss) on hedging activities, net of tax within the Company's unaudited Condensed Statements of Comprehensive Income (Loss) until the underlying third party transaction occurs. When the underlying third-party transaction occurs, the Company recognizes the gain or loss in earnings within Cost of Sales in its unaudited Condensed Consolidated Statements of Operations. The contracts are recorded at fair value and deemed to be Level Two in the fair value hierarchy.

At June 28, 2024, the Company's forward currency contracts have a Mexican Peso notional amount of approximately \$ 420.0 million and a U.S. Dollar aggregate notional amount of \$24.0 million. During the three and six months ended June 28, 2024, the Company recognized a realized gain of \$ 0.3 million and \$0.5 million, respectively on its Condensed Consolidated Statements of Operations related to its forward currency contracts designated as cash flow hedges. There was nothing recognized in the second quarter of 2023 as the Mexican Peso forward currency program was established in July 2023.

*Net Investment Hedges*

On April 18, 2023, the Company entered into cross-currency swap agreements to hedge its net investment in its Swiss Franc-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Swiss Franc. These swap agreements were designated and qualified as net investment hedges. These contracts had a Swiss Franc notional amount of approximately F403 million and a U.S. Dollar aggregate notional amount of \$450 million. In April 2024, the F 403 million cross-currency swap agreements designated as net investment hedges were de-designated and settled for \$4.6 million which is reflected as a cash outflow within investing activities in the Consolidated Statements of Cash Flows. The \$ 0.7 million gain on settlement is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive income (loss) and in the Company's Condensed Consolidated Statements of Comprehensive Income (Loss) as part of the foreign currency translation adjustment.

On April 8, 2024 and April 12, 2024 the Company entered into additional cross-currency swap agreements to hedge its net investment in its Swiss Franc-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Swiss Franc. These swap agreements are designated and qualify as net investment hedges. These contracts have a Swiss Franc notional amount of approximately F590 million and a U.S. Dollar aggregate notional amount of \$650 million at June 28, 2024.

Cross-currency swaps involve the receipt of functional-currency fixed-rate amounts from a counterparty in exchange for the Company making foreign-currency fixed-rate payments over the life of the agreement. For derivatives designated as net investment hedges, the gain or loss on the derivative is reported in the Condensed Consolidated Balance Sheet as part of Accumulated other comprehensive income (loss) and in the Company's Condensed Consolidated Statements of Comprehensive

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

Income (Loss) as part of the foreign currency translation adjustment. Amounts are reclassified out of Accumulated other comprehensive income (loss) into earnings when the hedged net investment is either sold or substantially liquidated.

During the three and six months ended June 28, 2024, the Company received interest income on its cross-currency swap derivatives of \$ 5.7 million and \$8.3 million which is included within Interest expense, net in the Condensed Consolidated Statements of Operations.

The following table presents the effect of the Company's designated hedging instruments on Accumulated other comprehensive income (loss) for the three and six months ended June 28, 2024 and 2023:

|   | Three Months Ended       |                          | Six Months Ended        |                         |
|---|--------------------------|--------------------------|-------------------------|-------------------------|
|   | June 28, 2024            | June 30, 2023            | June 28, 2024           | June 30, 2023           |
|   | (In thousands)           |                          |                         |                         |
| Gain (loss) on cross-currency swaps       | \$ (5,965)               | \$ (7,189)               | \$ 25,426               | \$ (7,18)               |
| Gain (loss) on forward currency contracts | (3,287)                  | —                        | (1,942)                 | —                       |
|   | <u><u>\$ (9,252)</u></u> | <u><u>\$ (7,189)</u></u> | <u><u>\$ 23,484</u></u> | <u><u>\$ (7,18)</u></u> |

*Non-Designated Hedging Instruments*

The Company also used non-designated forward currency contracts for the purpose of managing its exposure to currency exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition which closed in January 2024. In the first quarter of 2024, the Company recorded a loss of \$11.1 million on its Consolidated Statements of Operations related to the exchange rate movements over the first three days of 2024. The loss is recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations. From inception of the forward contracts on October 4, 2023 through the closing of the Lima Acquisition on January 3, 2024, the foreign currency forward contracts settled in an overall realized gain position of \$13.4 million.

The following table presents the fair value of the Company's derivative financial instruments as well as their classification on the Condensed Consolidated Balance Sheets as of June 28, 2024 and December 31, 2023:

| (In thousands)                            | Location on Unaudited Consolidated Balance Sheets <sup>(1)</sup> |                         | June 28, 2024           | December 31, 2023       |  |  |
|---|--|-------------------------|-------------------------|-------------------------|--|--|
|   | Sheets <sup>(1)</sup>  | June 28, 2024           |                         |                         |  |  |
| <b>Derivative Assets</b>                  |  |                         |                         |                         |  |  |
| <b>Designated Hedging Instruments</b>     |  |                         |                         |                         |  |  |
| Forward currency contracts                | Other current assets   | \$ —                    | \$ 432                  | 432                     |  |  |
| Cross-currency swaps                      | Other current assets   | <u><u>10,937</u></u>    | <u><u>10,061</u></u>    | <u><u>10,493</u></u>    |  |  |
| <b>Non-Designated Hedging Instruments</b> |  |                         |                         |                         |  |  |
| Forward currency contracts                | Other current assets   | <u><u>—</u></u>         | <u><u>24,311</u></u>    | <u><u>24,311</u></u>    |  |  |
| <b>Total Derivative Assets</b>            |  | <u><u>\$ 10,937</u></u> | <u><u>\$ 34,804</u></u> | <u><u>\$ 34,804</u></u> |  |  |
| <b>Derivative Liabilities</b>             |  |                         |                         |                         |  |  |
| <b>Designated Hedging Instruments</b>     |  |                         |                         |                         |  |  |
| Forward currency contracts                | Accrued liabilities  | \$ 1,528                | \$ 278                  | 278                     |  |  |
| Cross-currency swaps                      | Accrued liabilities  | 2,364                   | —                       | —                       |  |  |
| Cross-currency swaps                      | Other long-term liabilities                                      | <u><u>15,195</u></u>    | <u><u>46,953</u></u>    | <u><u>46,953</u></u>    |  |  |
| <b>Total Derivative Liabilities</b>       |  | <u><u>\$ 19,087</u></u> | <u><u>\$ 47,231</u></u> | <u><u>\$ 47,231</u></u> |  |  |

<sup>(1)</sup> The Company classifies derivative assets and liabilities as current when the settlement date of the contract is one year or less.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

## **12. Commitments and Contingencies**

The Company is involved in various pending legal, regulatory, and other proceedings arising out of the ordinary course of the Company's business. None of these proceedings are expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, management of the Company believes that either it will prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded as incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company.

For further description of the Company's litigation and contingencies, reference is made to Note 18, "Commitments and Contingencies" in the Notes to Consolidated Financial Statements in the Company's 2023 Form 10-K.

## **13. Segment Information**

The Company conducts its continuing operations through the Prevention & Recovery and Reconstructive operating segments, which also represent the Company's reportable segments.

- **P&R** - a leader in orthopedic solutions and recovery sciences, providing devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease.
- **Recon** - an innovation market-leader positioned in the fast-growing surgical implant business, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools.

The Company's management, including the chief operating decision maker, evaluates the operating results of each of its reportable segments based upon Net sales and Adjusted EBITDA, which excludes the effect of Other (income) expense, net, non-operating (gain) loss on investments, debt extinguishment charges, interest expense, net, restructuring and certain other charges, Medical Device Regulation (MDR) and other costs, strategic transaction costs, stock-based compensation, depreciation and other amortization, acquisition-related intangible asset amortization, insurance settlement loss (gain), and inventory step-up charges from the results of the Company's operating segments.

**ENOVIS CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — (Continued)**  
**(Unaudited)**

The Company's segment results were as follows:

|  | Three Months Ended |                   | Six Months Ended    |                   |
|--|--------------------|-------------------|---------------------|-------------------|
|  | June 28, 2024      | June 30, 2023     | June 28, 2024       | June 30, 2023     |
|  | (In thousands)     |                   |                     |                   |
| <b>Net Sales:</b>                              |                    |                   |                     |                   |
| Prevention & Recovery                          | \$ 277,754         | \$ 273,475        | \$ 536,767          | \$ 524,215        |
| Reconstructive                                 | 247,406            | 155,027           | 504,659             | 310,438           |
|  | <u>\$ 525,160</u>  | <u>\$ 428,502</u> | <u>\$ 1,041,426</u> | <u>\$ 834,653</u> |
| <b>Segment Adjusted EBITDA <sup>(1)</sup>:</b> |                    |                   |                     |                   |
| Prevention & Recovery                          | \$ 41,141          | \$ 39,323         | \$ 69,064           | \$ 65,018         |
| Reconstructive                                 | 49,073             | 26,359            | 104,384             | 57,075            |
|  | <u>\$ 90,214</u>   | <u>\$ 65,682</u>  | <u>\$ 173,448</u>   | <u>\$ 122,093</u> |

<sup>(1)</sup> The following is a reconciliation of Income (loss) from continuing operations before income taxes to Adjusted EBITDA:

|  | Three Months Ended |                  | Six Months Ended  |                   |
|--|--------------------|------------------|-------------------|-------------------|
|  | June 28, 2024      | June 30, 2023    | June 28, 2024     | June 30, 2023     |
|  | (In thousands)     |                  |                   |                   |
| Loss from continuing operations before income taxes (GAAP) | \$ (27,352)        | \$ (19,323)      | \$ (106,597)      | \$ (49,282)       |
| Restructuring and other costs <sup>(1)</sup>               | 4,587              | 3,806            | 17,498            | 6,742             |
| MDR and other costs <sup>(2)</sup>                         | 4,542              | 8,997            | 9,460             | 16,793            |
| Strategic transaction costs <sup>(3)</sup>                 | 22,693             | 5,435            | 43,530            | 17,065            |
| Stock-based compensation                                   | 7,641              | 8,868            | 14,041            | 15,776            |
| Depreciation and other amortization                        | 30,127             | 20,794           | 57,300            | 40,745            |
| Amortization of acquired intangibles                       | 40,936             | 32,249           | 81,867            | 64,289            |
| Inventory step-up  | 23,908             | 27               | 28,985            | 146               |
| Interest expense, net                                      | 16,969             | 4,076            | 36,965            | 9,728             |
| Other (income) expense, net <sup>(4)</sup>                 | <u>(33,836)</u>    | <u>753</u>       | <u>(9,601)</u>    | <u>92</u>         |
| Adjusted EBITDA (non-GAAP)                                 | <u>\$ 90,214</u>   | <u>\$ 65,682</u> | <u>\$ 173,448</u> | <u>\$ 122,093</u> |

<sup>(1)</sup> Restructuring and other charges includes \$— million and \$0.3 million of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023.

<sup>(2)</sup> Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Devices Regulation. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

<sup>(3)</sup> Primarily relates to integration costs associated with the Lima Acquisition in 2024 and other strategic initiatives in 2023, including costs related to the Separation.

<sup>(4)</sup> Primarily includes the fair value gain on Contingent Acquisition shares, partially offset by the first quarter of 2024 loss on the non-designated forward currency hedge for managing exchange rate risk related to the Euro-denominated purchase price of the Lima Acquisition.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations****MANAGEMENT'S DISCUSSION AND ANALYSIS OF  
FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion of the financial condition and results of operations of Enovis Corporation ("Enovis," "the Company," "we," "our," and "us") should be read in conjunction with the Condensed Consolidated Financial Statements and related footnotes included in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2024 (this "Form 10-Q") and the Consolidated Financial Statements and related footnotes included in Part II, Item 8, "Financial Statements and Supplementary Data" of our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K") filed with the Securities and Exchange Commission (the "SEC") on February 22, 2024.*

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

Some of the statements contained in this Form 10-Q that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Form 10-Q is filed with the SEC. Statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding: the Company's recently completed acquisition (the "Lima Acquisition") of LimaCorporate S.p.A. ("Lima"); the impacts of the completed spin-off of ESAB Corporation ("ESAB") into an independent publicly traded company (the "Separation"); the expected financial and operating performance of, and future opportunities for, the Company following the Separation; the impact of public health emergencies and global pandemics (including COVID-19); projections of revenue, profit margins, expenses, tax provisions and tax rates, earnings or losses from operations, impact of foreign exchange rates, cash flows, synergies or other financial items; plans, strategies and objectives of management for future operations including statements relating to potential acquisitions, compensation plans or purchase commitments; developments, performance, industry or market rankings relating to products or services; future economic conditions or performance, including the impact of inflationary pressures; the outcome of outstanding claims or legal proceedings; potential gains and recoveries of costs; assumptions underlying any of the foregoing; and any other statements that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements may be characterized by terminology such as "believe," "anticipate," "should," "would," "could," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy," "targets," "aims," "seeks," "sees," and similar expressions. These statements are based on assumptions and assessments made by our management as of the filing of this Form 10-Q in light of their experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties and actual results could differ materially due to numerous factors, including but not limited to the following:

- the effects of the Lima Acquisition on the Company's and Lima's combined operations, including any effects on relationships with customers, suppliers and other third parties;
- an inability to identify, finance, acquire and successfully integrate suitable acquisition candidates;
- the availability of additional capital and our inability to pursue our growth strategy without it;
- our indebtedness and our debt agreements, which contain restrictions that may limit our flexibility in operating our business;
- our restructuring activities, which may subject us to additional uncertainty in our operating results;
- any impairment in the value of our intangible assets or goodwill, because of a sustained decline, including but not limited to, operating performance at one or more our business units or the market price of our common stock;
- a material disruption at any of our manufacturing facilities;
- any failure to maintain, protect and defend our intellectual property rights;

- the effects of contagious diseases, such as the COVID-19 pandemic, terrorist activity, man-made or natural disasters and war;
- significant movements in foreign currency exchange rates;
- the availability of raw materials, as well as parts and components used in our products, as well as the impact of raw material, energy and labor price fluctuations and supply shortages;
- the competitive environment in which we operate;
- our reliance on a variety of distribution methods to market and sell our medical device products;
- extensive government regulation and oversight of our products, including the requirement to obtain and maintain regulatory approvals and clearances;
- safety issues or recalls of our products;
- failure to comply with federal and state regulations related to the manufacture of our products;
- improper marketing or promotion of our products;
- impacts of potential legislative or regulatory reforms on our business;
- risks associated with the clinical trial process;
- failure to comply with governmental regulations for products for which we obtain clearance or approval;
- our exposure to product liability claims;
- our inability to obtain coverage and adequate levels of reimbursement from third-party payors for our medical device products;
- audits or denials of claims by government officials;
- federal and state health reform and cost control efforts;
- our failure or the failure of our employees or third parties with which we have relationships to comply with healthcare laws and regulations;
- our relationships with leading surgeons and our ability to comply with enhanced disclosure requirements regarding payments to physicians;
- actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements;
- service interruptions, data corruption, cyber-based attacks or network security breaches affecting our information technology infrastructure;
- non-compliance with anti-bribery laws, export control regulations, economic sanctions or other trade laws;
- non-compliance with non-U.S. laws, regulations and policies;
- our inability to achieve some or all of the expected benefits of the Separation;
- if the Separation and/or certain related transactions do not qualify as transactions that are generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities;

- potential indemnification liabilities to ESAB pursuant to the Separation and distribution agreement and other related agreements;
- changes in the general economy;
- disruptions in the global economy caused by escalating geopolitical tensions, including in connection with Russia's invasion of Ukraine;
- the loss of key members of our leadership team, or the inability to attract, develop, engage, and retain qualified employees; and
- other risks and factors listed in Part II, Item 1A. "Risk Factors" in this Form 10-Q and Part 1, Item 1A. "Risk Factors" in Part I of our 2023 Form 10-K.

Any such forward-looking statements are not guarantees of future performance and actual results, developments and business decisions may differ materially from those envisaged by such forward-looking statements. We do not assume any obligation and do not intend to update any forward-looking statement, except as required by law. See "Risk Factors" in this Form 10-Q and our 2023 Form 10-K for a further discussion regarding some of the reasons that actual results may be materially different from those that we anticipate.

## Overview

Please see Part I, Item 1. "Business" in our 2023 Form 10-K for a discussion of the Company's objectives and methodologies for delivering shareholder value.

Enovis conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon").

- **P&R** - a leader in orthopedic solutions, providing devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease.
- **Recon** - an innovation market-leader positioned in the fast-growing surgical implant business, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools.

We have a global footprint, with production facilities in North America, Europe, North Africa, and Asia. We serve a global customer base across multiple markets through a combination of direct sales and third-party distribution channels. Our customer base is highly diversified in the medical market.

Our business management system, Enovis Growth Excellence ("EGX"), is integral to our operations. EGX includes our values and behaviors, a comprehensive set of tools, and repeatable, teachable processes that we use to drive continuous improvement and create superior value for our customers, shareholders, and associates. We believe that our management team's access to, and experience in, the application of the EGX methodology is one of our primary competitive strengths.

## Results of Operations

The following discussion of Results of Operations addresses the comparison of the periods presented. Our management evaluates the operating results of each of its reportable segments based upon Net sales, Adjusted EBITDA, Comparable sales, and Comparable sales growth rate as defined in the "Non-GAAP Measures" section below.

### *Items Affecting Comparability of Reported Results and Other Recent Developments*

The comparability of our operating results for the three and six months ended June 28, 2024 to the prior periods in 2023 is affected by the following significant items:

#### Strategic Acquisitions

We complement our organic growth plans with strategic acquisitions. Acquisitions can significantly affect our reported results.

On January 3, 2024, the Company acquired Lima, a privately held global orthopedic company focused on restoring motion through digital innovation and customized hardware for total fair value consideration of \$866.5 million, net of acquired cash. The fair value total consideration includes a fixed number contingently issuable shares of Enovis stock valued at \$107.9 million, which is dependent on the non-occurrence of certain future events and is expected to be settled within one year of the acquisition closing. Subsequent to the end of the second quarter of 2024, the first tranche of the Contingent Acquisition Shares of 971,343 shares were issued to the sellers on July 16, 2024. This acquisition expands and complements our current product offerings internationally within our Recon segment.

During the year ended December 31, 2023, we completed one acquisition accounted for as a business combination and two asset acquisitions in our Recon segment. On June 28, 2023, we acquired Novastep, a leading player in Minimally Invasive Surgery (MIS) foot and ankle solutions for total consideration of \$96.9 million. The Novastep best-in-class MIS bunion system serves a rapidly growing portion of the global bunion segment. On July 20, 2023, we completed an asset acquisition of a broad line of external fixation products from D.N.E., LLC for total consideration of \$28.2 million. These two acquisitions are valuable additions serving to enhance the offerings under our foot & ankle product lines. On October 5, 2023, we acquired a 100% interest in Precision AI, a developer of surgical planning software. The acquisition of Precision AI complements our current

product offerings with advanced surgical planning software. The software has capabilities to be used for shoulder reconstruction and there is an opportunity to expand this to additional anatomies.

#### Foreign Currency Fluctuations

During the three and six months ended June 28, 2024, approximately 41% and 42% of our sales, respectively, were derived from operations outside the United States, the majority of which are in Europe, with the remaining portion primarily in the Asia-Pacific region. Accordingly, we can be affected by market demand, economic and political factors in countries in Europe and the Asia-Pacific region, and significant movements in foreign exchange rates. Our ability to grow and our financial performance will be affected by our ability to address challenges and opportunities that are a consequence of expanding our global operations through our recent acquisitions, including efficiently utilizing our international sales channels, manufacturing and distribution capabilities, participating in the expansion of market opportunities, successfully completing global acquisitions and engineering innovative new product applications to create better patient outcomes.

The majority of our Net sales derived from operations outside the United States are denominated in currencies other than the U.S. Dollar. Similar portions of our manufacturing and employee costs are also outside the United States and denominated in currencies other than the U.S. Dollar. Changes in foreign exchange rates can impact our results of operations and are quantified when significant. For the three months ended June 28, 2024 compared to the three months ended June 30, 2023, fluctuations in foreign currencies decreased Net sales by 0.3%, decreased Gross profit by approximately 0.6%, and decreased operating expense by approximately 0.3%. For the six months ended June 28, 2024 compared to the six months ended June 30, 2023, fluctuations in foreign currencies had immaterial impact on Net sales, decreased Gross profit by approximately 0.4%, and increased operating expenses by approximately 0.1%.

#### Seasonality

Sales in our P&R and Recon segments typically peak in the fourth quarter. General economic conditions and other factors may, however, impact future seasonal variations.

## Non-GAAP Measures

### Adjusted EBITDA; Comparable sales

Adjusted EBITDA, Adjusted EBITDA margin, Comparable sales, and Comparable sales growth rate, which are non-GAAP performance measures, are included in this report because they are key metrics used by our management to assess our operating performance.

Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income tax expense (benefit); Other (income) expense, net; non-operating (gain) loss on investments; debt extinguishment charges; Interest expense, net; Restructuring and other charges; Medical Device Regulation ("MDR") fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement gain; and fair value charges on acquired inventory. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

Comparable sales adjusts nets sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of certain non-core product lines that were divested or discontinued, as applicable, during the periods presented. The acquired businesses include Lima and Novastep, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of the divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment. Comparable sales growth rate represents the change in Comparable sales for the current period from Comparable sales for the prior year period. Comparable sales and Comparable sales growth rate assist our management in evaluating operating performance over time because the impact of significant acquisitions and divestitures or discontinuance of certain non-core product lines subsequent to prior periods may obscure underlying business trends and make the evaluation of period-over-period performance difficult. Comparable sales and Comparable sales growth rate are presented for illustrative purposes only and do not and are not intended to comply with Article 11 of Regulation S-X promulgated by the SEC in respect of proforma financial information, and may differ, including materially, from proforma financial statements presented in accordance therewith.

Our management also believes that presenting these measures allows investors to view our performance using the same measures that we use in evaluating our financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP or prepared in accordance with Regulation S-X. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. The following tables set forth a reconciliation of net income (loss) from continuing operations, the most directly comparable financial statement measure, to Adjusted EBITDA, for the three and six months ended June 28, 2024 and June 30, 2023, respectively.

|  | Three Months Ended    |           |           |               |           |           |
|--|-----------------------|-----------|-----------|---------------|-----------|-----------|
|  | June 28, 2024         |           |           | June 30, 2023 |           |           |
|  | P&R                   | Recon     | Total     | P&R           | Recon     | Total     |
|  | (Dollars in millions) |           |           |               |           |           |
| Net income (loss) from continuing operations (GAAP) <sup>(1)</sup> |                       |           | \$ (18.4) |               |           | \$ (14.6) |
| Income tax expense (benefit)                                       |                       |           | (8.9)     |               |           | (4.7)     |
| Other (income) expense, net  |                       |           | (33.8)    |               |           | 0.8       |
| Interest expense, net  |                       |           | 17.0      |               |           | 4.1       |
| Operating income (loss) (GAAP)                                     | \$ 2.5                | \$ (46.8) | \$ (44.2) | \$ (4.4)      | \$ (10.1) | \$ (14.5) |
| Operating income (loss) margin                                     | 0.9 %                 | (18.9)%   | (8.4)%    | (1.6)%        | (6.5)%    | (3.4)%    |
| Adjusted to add (deduct):  |                       |           |           |               |           |           |
| Restructuring and other charges <sup>(2)</sup>                     | 1.8                   | 2.8       | 4.6       | 2.0           | 1.8       | 3.8       |
| MDR and other costs <sup>(2)</sup>                                 | 2.1                   | 2.4       | 4.5       | 5.0           | 4.0       | 9.0       |
| Strategic transaction costs <sup>(2)</sup>                         | 1.9                   | 20.8      | 22.7      | 1.8           | 3.7       | 5.4       |
| Stock-based compensation <sup>(2)</sup>                            | 5.4                   | 2.3       | 7.6       | 5.8           | 3.0       | 8.9       |
| Depreciation and other amortization                                | 4.5                   | 25.6      | 30.1      | 5.8           | 15.0      | 20.8      |
| Amortization of acquired intangibles                               | 22.9                  | 18.0      | 40.9      | 23.4          | 8.9       | 32.2      |
| Inventory step-up  | —                     | 23.9      | 23.9      | —             | —         | —         |
| Adjusted EBITDA (non-GAAP)   | \$ 41.1               | \$ 49.1   | \$ 90.2   | \$ 39.3       | \$ 26.4   | \$ 65.7   |
| Adjusted EBITDA margin (non-GAAP)                                  | 14.8 %                | 19.8 %    | 17.2 %    | 14.4 %        | 17.0 %    | 15.3 %    |

<sup>(1)</sup> Non-operating components of Net income (loss) from continuing operations are not allocated to the segments.

<sup>(2)</sup> Certain amounts are allocated to the segments as a percentage of revenue as the costs are not discrete to either segment.

|  | Six Months Ended      |           |           |               |           |           |
|--|-----------------------|-----------|-----------|---------------|-----------|-----------|
|  | June 28, 2024         |           |           | June 30, 2023 |           |           |
|  | P&R                   | Recon     | Total     | P&R           | Recon     | Total     |
|  | (Dollars in millions) |           |           |               |           |           |
| Net income (loss) from continuing operations (GAAP) <sup>(1)</sup> |                       |           | \$ (90.3) |               |           | \$ (37.5) |
| Income tax expense (benefit)                                       |                       |           | (16.3)    |               |           | (11.8)    |
| Other (income) expense, net  |                       |           | (9.6)     |               |           | 0.1       |
| Interest expense, net  |                       |           | 37.0      |               |           | 9.7       |
| Operating income (loss) (GAAP)                                     | \$ (11.4)             | \$ (67.8) | \$ (79.2) | \$ (22.6)     | \$ (16.9) | \$ (39.5) |
| Operating income (loss) margin                                     | (2.1)%                | (13.4)%   | (7.6)%    | (4.9)%        | (5.4)%    | (4.7)%    |
| Adjusted to add (deduct):  |                       |           |           |               |           |           |
| Restructuring and other charges <sup>(2)(3)</sup>                  | 9.5                   | 8.0       | 17.5      | 3.3           | 3.4       | 6.7       |
| MDR and other costs <sup>(3)</sup>                                 | 5.2                   | 4.3       | 9.5       | 8.2           | 8.6       | 16.8      |
| Strategic transaction costs <sup>(3)</sup>                         | 2.0                   | 41.5      | 43.5      | 8.0           | 9.1       | 17.1      |
| Stock-based compensation <sup>(3)</sup>                            | 8.6                   | 5.5       | 14.0      | 9.9           | 5.9       | 15.8      |
| Depreciation and other amortization                                | 9.1                   | 48.2      | 57.3      | 11.5          | 29.3      | 40.7      |
| Amortization of acquired intangibles                               | 46.1                  | 35.7      | 81.9      | 46.7          | 17.6      | 64.3      |
| Inventory step-up  | —                     | 29.0      | 29.0      | —             | 0.1       | 0.1       |
| Adjusted EBITDA (non-GAAP)   | \$ 69.1               | \$ 104.4  | \$ 173.4  | \$ 65.0       | \$ 57.1   | \$ 122.1  |
| Adjusted EBITDA margin (non-GAAP)                                  | 12.9%                 | 20.7%     | 16.6%     | 12.4%         | 18.4%     | 14.6%     |

<sup>(1)</sup> Non-operating components of Net income (loss) from continuing operations are not allocated to the segments.

<sup>(2)</sup> Restructuring and other charges includes \$0.3 million of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the six months ended June 30, 2023.

<sup>(3)</sup> Certain amounts are allocated to the segments as a percentage of revenue as the costs are not discrete to either segment.

**Total Company**

**Sales**

The following table summarizes our sales for the three and six months ended June 28, 2024, respectively.

|                                   | Three Months Ended |                 |               | Six Months Ended  |                 |               |  |  |  |  |  |  |
|-----------------------------------|--------------------|-----------------|---------------|-------------------|-----------------|---------------|--|--|--|--|--|--|
|                                   | June 28, 2024      | June 30, 2023   | Growth Rate   | June 28, 2024     | June 30, 2023   | Growth Rate   |  |  |  |  |  |  |
|                                   | GAAP               |                 |               | GAAP              |                 |               |  |  |  |  |  |  |
| (In millions)                     |                    |                 |               |                   |                 |               |  |  |  |  |  |  |
| <b>Prevention &amp; Recovery:</b> |                    |                 |               |                   |                 |               |  |  |  |  |  |  |
| U.S. Bracing & Support            | \$ 117.5           | \$ 115.0        | 2.2 %         | \$ 222.1          | \$ 219.3        | 1.3 %         |  |  |  |  |  |  |
| U.S. Other P&R                    | 68.0               | 67.7            | 0.3 %         | 134.3             | 130.1           | 3.2 %         |  |  |  |  |  |  |
| International P&R                 | 92.3               | 90.8            | 1.6 %         | 180.4             | 174.8           | 3.2 %         |  |  |  |  |  |  |
| Total Prevention & Recovery       | 277.8              | 273.5           | 1.6 %         | 536.8             | 524.2           | 2.4 %         |  |  |  |  |  |  |
| <b>Reconstructive:</b>            |                    |                 |               |                   |                 |               |  |  |  |  |  |  |
| U.S. Reconstructive               | 122.1              | 106.1           | 15.0 %        | 245.8             | 209.6           | 17.2 %        |  |  |  |  |  |  |
| International Reconstructive      | 125.3              | 48.9            | 156.4 %       | 258.9             | 100.8           | 156.8 %       |  |  |  |  |  |  |
| Total Reconstructive              | 247.4              | 155.0           | 59.6 %        | 504.7             | 310.4           | 62.6 %        |  |  |  |  |  |  |
| <b>Total</b>                      | <b>\$ 525.2</b>    | <b>\$ 428.5</b> | <b>22.6 %</b> | <b>\$ 1,041.4</b> | <b>\$ 834.7</b> | <b>24.8 %</b> |  |  |  |  |  |  |

The following table summarizes sales on a Comparable sales and Comparable sales growth rate basis for the periods presented.

|                                   | Three Months Ended              |                 |              | Six Months Ended                |                 |              |  |  |  |  |  |  |
|-----------------------------------|---------------------------------|-----------------|--------------|---------------------------------|-----------------|--------------|--|--|--|--|--|--|
|                                   | June 28, 2024                   | June 30, 2023   | Growth Rate  | June 28, 2024                   | June 30, 2023   | Growth Rate  |  |  |  |  |  |  |
|                                   | Comparable sales <sup>(1)</sup> |                 |              | Comparable sales <sup>(1)</sup> |                 |              |  |  |  |  |  |  |
| (In millions)                     |                                 |                 |              |                                 |                 |              |  |  |  |  |  |  |
| <b>Prevention &amp; Recovery:</b> |                                 |                 |              |                                 |                 |              |  |  |  |  |  |  |
| U.S. Bracing & Support            | \$ 117.5                        | \$ 115.0        | 2.2 %        | \$ 222.1                        | \$ 219.3        | 1.3 %        |  |  |  |  |  |  |
| U.S. Other P&R                    | 68.0                            | 65.3            | 4.0 %        | 131.6                           | 125.2           | 5.1 %        |  |  |  |  |  |  |
| International P&R                 | 92.3                            | 89.4            | 3.2 %        | 178.7                           | 172.1           | 3.8 %        |  |  |  |  |  |  |
| Total Prevention & Recovery       | 277.8                           | 269.7           | 3.0 %        | 532.4                           | 516.7           | 3.0 %        |  |  |  |  |  |  |
| <b>Reconstructive:</b>            |                                 |                 |              |                                 |                 |              |  |  |  |  |  |  |
| U.S. Reconstructive               | 122.1                           | 120.7           | 1.1 %        | 245.8                           | 239.6           | 2.6 %        |  |  |  |  |  |  |
| International Reconstructive      | 125.3                           | 111.4           | 12.5 %       | 258.4                           | 229.9           | 12.4 %       |  |  |  |  |  |  |
| Total Reconstructive              | 247.4                           | 232.1           | 6.6 %        | 504.2                           | 469.5           | 7.4 %        |  |  |  |  |  |  |
| <b>Total</b>                      | <b>\$ 525.2</b>                 | <b>\$ 501.8</b> | <b>4.7 %</b> | <b>\$ 1,036.6</b>               | <b>\$ 986.2</b> | <b>5.1 %</b> |  |  |  |  |  |  |

<sup>(1)</sup> Comparable sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of divested businesses and certain discontinued Recon products lines in conjunction with the Lima Acquisition. The acquired businesses include Lima and Novastep, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of a divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment.

Net sales for the three months ended June 28, 2024 increased from the prior year by \$96.7 million, or 22.6% primarily attributable to an increase in sales from the Lima Acquisition and to a lesser extent the Novastep acquisition and growth in existing businesses. Recon sales increased by \$92.4 million, or 59.6%, of which \$90.1 million was attributable to the Lima and the Novastep acquisitions. Recon sales were negatively impacted by a \$2.2 million decrease from the discontinuance of certain non-core product lines. P&R increased by \$4.3 million, or 1.6%, which was negatively impacted by a \$3.8 million decrease in

sales from divesting a minor product line. For the three months ended June 30, 2023, U.S. GAAP basis net sales were \$428.5 million. The Comparable sales were \$501.8 million for the same period. In 2023, Lima and Novastep would have contributed \$79.2 million to Comparable sales, offset by the impact of the divestiture and discontinuance of certain non-core product lines of \$5.9 million. Comparable sales growth for Recon was driven by approximately 7.1% increases in volume and market share gains, offset by unfavorable currency translation of 0.5%. Comparable sales growth for P&R was driven by approximately 3.3% organic growth in volumes, offset by 0.3% unfavorable foreign currency translation. The strengthening of the U.S. Dollar relative to other currencies resulted in \$2.0 million, or 0.4%, of unfavorable foreign currency translation impacts on total net sales for the three months ended June 28, 2024 from the prior year period.

Net sales for the six months ended June 28, 2024 increased from the prior year by \$206.8 million, or 24.8% primarily attributable to an increase in sales from the Lima Acquisition and to a lesser extent the Novastep acquisition and growth in existing businesses. Recon sales increased by \$194.2 million, or 62.6%, of which \$183.7 million was attributable to the Lima and the Novastep acquisitions. Recon sales were negatively impacted by a \$4.6 million decrease from the discontinuance of certain non-core product lines. P&R sales increased by \$12.6 million, or 2.4%, which was negatively impacted by a \$3.2 million decrease from divesting a minor product line. For the six months ended June 28, 2024, U.S. GAAP basis net sales were \$1,041.4 million. The Comparable sales were \$1,036.6 million for the same period. For the six months ended June 28, 2024, the sales attributable to the non-core product lines, which were divested or discontinued, were \$4.8 million. For the six months ended June 30, 2023, U.S. GAAP basis net sales were \$834.7 million. The Comparable sales were \$986.2 million for the same period. In 2023, Lima and Novastep would have contributed \$164.2 million to Comparable sales, offset by the impact of the divestiture and discontinuance of certain non-core product lines of \$12.6 million. Comparable sales growth for Recon was driven by approximately 7.0% increases in volume and market share gains and favorable foreign currency translation of 0.4%. Comparable sales growth for P&R was driven by approximately 3.1% organic growth in volumes, offset by 0.1% unfavorable foreign currency translation. The weakening of the U.S. Dollar relative to other currencies resulted in \$1.4 million, or 0.1%, of favorable foreign currency translation impacts on total net sales for the six months ended June 28, 2024 from the prior year period.

### Operating Results

The following table summarizes our results of continuing operations for the current year and prior year periods.

|   | Three Months Ended |               | Six Months Ended |               |
|---|--------------------|---------------|------------------|---------------|
|   | June 28, 2024      | June 30, 2023 | June 28, 2024    | June 30, 2023 |
| (Dollars in millions)                             |                    |               |                  |               |
| Gross profit                                      | \$ 288.9           | \$ 248.4      | \$ 586.8         | \$ 483.4      |
| Gross profit margin                               | 55.0 %             | 58.0 %        | 56.3 %           | 57.9 %        |
| Selling, general and administrative expense       | \$ 264.1           | \$ 207.9      | \$ 519.8         | \$ 415.0      |
| Research and development expense                  | \$ 23.5            | \$ 18.9       | \$ 46.9          | \$ 37.1       |
| Operating loss                                    | \$ (44.2)          | \$ (14.5)     | \$ (79.2)        | \$ (39.5)     |
| Operating loss margin                             | (8.4)%             | (3.4)%        | (7.6)%           | (4.7)%        |
| Net loss from continuing operations               | \$ (18.4)          | \$ (14.6)     | \$ (90.3)        | \$ (37.5)     |
| Net loss from continuing operations margin (GAAP) | (3.5)%             | (3.4)%        | (8.7)%           | (4.5)%        |
| Adjusted EBITDA (non-GAAP)                        | \$ 90.2            | \$ 65.7       | \$ 173.4         | \$ 122.1      |
| Adjusted EBITDA margin (non-GAAP)                 | 17.2 %             | 15.3 %        | 16.7 %           | 14.6 %        |
| Items excluded from Adjusted EBITDA:              |                    |               |                  |               |
| Restructuring and other charges <sup>(1)</sup>    | \$ 4.6             | \$ 3.8        | \$ 17.5          | \$ 6.7        |
| MDR and other costs                               | \$ 4.5             | \$ 9.0        | \$ 9.5           | \$ 16.8       |
| Strategic transaction costs                       | \$ 22.7            | \$ 5.4        | \$ 43.5          | \$ 17.1       |
| Stock-based compensation                          | \$ 7.6             | \$ 8.9        | \$ 14.0          | \$ 15.8       |
| Depreciation and other amortization               | \$ 30.1            | \$ 20.8       | \$ 57.3          | \$ 40.7       |
| Amortization of acquired intangibles              | \$ 40.9            | \$ 32.2       | \$ 81.9          | \$ 64.3       |
| Inventory step-up                                 | \$ 23.9            | \$ —          | \$ 29.0          | \$ 0.1        |
| Interest expense, net                             | \$ 17.0            | \$ 4.1        | \$ 37.0          | \$ 9.7        |
| Other expense (income) net                        | \$ (33.8)          | \$ 0.8        | \$ (9.6)         | \$ 0.1        |
| Income tax benefit                                | \$ (8.9)           | \$ (4.7)      | \$ (16.3)        | \$ (11.8)     |

<sup>(1)</sup> Restructuring and other charges includes \$0.3 million of expense classified as Cost of sales on the Company's Condensed Consolidated Statements of Operations for the six months ended June 30, 2023.

#### *Three Months Ended June 28, 2024 Compared to Prior Year*

Gross profit increased in the three months ended June 28, 2024 compared with the prior year period due to a \$36.6 million increase in our Recon segment and a \$3.9 million increase in our P&R segment. The Gross profit increase was attributable to increased sales from the Lima and Novastep acquisitions, offset by an increase of \$23.9 million in inventory fair value step-up amortization charges. Gross profit margin decreased by (3.0)% due to the aforementioned increase in inventory fair value step-up amortization charges.

Selling, general and administrative expense increased \$56.2 million in the three months ended June 28, 2024 compared to the prior year period, primarily due to increased commissions on increased sales and increased selling, general and administrative costs from the Lima Acquisition. Research and development costs also increased compared to the prior year period, primarily due to the Lima Acquisition and increased spend within recently acquired businesses in our Recon segment, which is investing in surgical productivity solutions and computer-assisted surgery technologies. Amortization of acquired intangibles and Depreciation and other amortization also increased compared to the prior year period due to the Lima Acquisition.

Interest expense, net increased in the three months ended June 28, 2024 compared to the prior year period due to an increase in debt to finance the Lima Acquisition.

The effective tax rate for Net loss from continuing operations during the three months ended June 28, 2024 was 32.6%, which was higher than the 2024 U.S. federal statutory tax rate of 21%, primarily due to tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares. This was partially offset by an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations. The effective tax rate for Net loss from continuing operations during the three months ended June 30, 2023 was 24.4%, which was higher than the 2023 U.S. federal statutory tax rate of 21%, primarily due to non-U.S. income being taxed at lower rates, the release of a valuation allowance on non-U.S. attributes, tax credits for research and development, and release of uncertain tax positions. This was partially offset by other non-deductible expenses and the U.S. taxation on international operations.

Net loss from continuing operations increased in the three months ended June 28, 2024 compared with the prior year period, primarily due to a \$17.3 million increase in strategic transactions costs from Lima integration activities, a \$12.9 million increase in interest expense, net, and \$8.7 million increase in amortization of acquired intangibles, offset by a \$33.5 million mark-to-market gain on the Contingent Acquisition Shares liability. Adjusted EBITDA and aEBITDA margin increased due to the Lima Acquisition.

#### *Six Months Ended June 28, 2024 Compared to Prior Year*

Gross profit increased in the six months ended June 28, 2024 compared with the prior year period due to a \$94.9 million increase in our Recon segment and a \$8.2 million increase in our P&R segment. The Gross profit increase was attributable to increased sales from the Lima and Novastep acquisitions, offset by an increase of \$28.8 million in inventory fair value step-up amortization charges. Gross profit margin decreased by 1.6% due to the aforementioned increase in inventory fair value step-up amortization charges.

Selling, general and administrative expense increased \$104.8 million in the six months ended June 28, 2024 compared to the prior year period, primarily due to increased commissions on increased sales and increased selling, general and administrative costs from the Lima Acquisition. Research and development costs also increased compared to the prior year period, primarily due to the Lima Acquisition and increased spend within recently acquired businesses in our Recon segment, which is investing in surgical productivity solutions and computer-assisted surgery technologies. Amortization of acquired intangibles and Depreciation and other amortization also increased compared to the prior year period due to the Lima Acquisition.

Interest expense, net increased in the six months ended June 28, 2024 compared to the prior year period due to an increase in debt to finance the Lima Acquisition.

The effective tax rate for Net loss from continuing operations during the six months ended June 28, 2024 was 15.3%, which was lower than the 2024 U.S. federal statutory tax rate of 21%, primarily due to an increase in valuation allowance on interest limitation carryforwards, non-deductible expenses and U.S. taxation on international operations. This was partially offset by tax credits for research and development, non-U.S. income taxed at lower rates and non-taxable fair value gain on contingent acquisition shares. The effective tax rate for Net income from continuing operations during the six months ended June 30, 2023 was 24.0%, which was higher than the 2023 U.S. federal statutory tax rate of 21%, primarily due to non-U.S. income being taxed at lower rates, the release of a valuation allowance on non-U.S. attributes, tax credits for research and development, and release of uncertain tax positions. This was partially offset by other non-deductible expenses and the U.S. taxation on international operations.

Net loss from continuing operations increased in the six months ended June 28, 2024 compared with the prior year period by \$52.8 million, primarily due to the \$27.3 million increase in interest expense, net, a \$37.2 million net increase in strategic transaction and restructuring costs driven by Lima activities, a loss of \$11.1 million on the non-designated forward currency contracts for the Lima Acquisition, offset by a \$20.1 million mark-to-market gain on the Contingent Acquisition Shares liability. Adjusted EBITDA and aEBITDA margin increased due to the Lima Acquisition.

#### *Business Segments*

As discussed further above, we report results in two reportable segments: P&R and Recon. Operating loss, adjusted EBITDA, and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. See Item 2. "Non-GAAP Measures" for a further discussion and reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures.

#### Prevention & Recovery

We develop, manufacture, and distribute rigid bracing products, orthopedic soft goods, vascular systems, and compression garments, and hot and cold therapy products and offer robust recovery sciences products in the clinical rehabilitation and sports medicine markets such as bone growth stimulators and electrical stimulators used for pain management. Our Prevention & Recovery products are marketed under several brand names, most notably DJO, to orthopedic specialists, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals who treat patients with a variety of treatment needs including musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events and sports-related injuries. Many of our medical devices and related accessories are used by athletes and other patients for injury prevention and at-home physical therapy treatments. We reach a diverse customer base through multiple distribution channels, including independent distributors, direct salespeople, and directly to patients.

The following table summarizes selected financial results for our Prevention & Recovery segment:

|  | Three Months Ended    |  |               |  | Six Months Ended |  |               |  |
|--|-----------------------|--|---------------|--|------------------|--|---------------|--|
|  | June 28, 2024         |  | June 30, 2023 |  | June 28, 2024    |  | June 30, 2023 |  |
|  | (Dollars in millions) |  |               |  |                  |  |               |  |
| Net sales                                    | \$ 277.8              |  | \$ 273.5      |  | \$ 536.8         |  | \$ 524.2      |  |
| Gross profit                                 | \$ 146.2              |  | \$ 142.2      |  | \$ 277.5         |  | \$ 269.2      |  |
| Gross profit margin                          | 52.6 %                |  | 52.0 %        |  | 51.7 %           |  | 51.4 %        |  |
| Selling, general and administrative expenses | \$ 109.7              |  | \$ 112.4      |  | \$ 215.2         |  | \$ 224.6      |  |
| Research and development expense             | \$ 9.2                |  | \$ 8.9        |  | \$ 18.0          |  | \$ 17.4       |  |
| Amortization of acquired intangibles         | \$ 22.9               |  | \$ 23.4       |  | \$ 46.1          |  | \$ 46.7       |  |
| Restructuring and other charges              | \$ 1.8                |  | \$ 2.0        |  | \$ 9.5           |  | \$ 3.1        |  |
| Operating income (loss) (GAAP)               | \$ 2.5                |  | \$ (4.4)      |  | \$ (11.4)        |  | \$ (22.6)     |  |
| Operating loss margin (GAAP)                 | 0.9 %                 |  | (1.6) %       |  | (2.1) %          |  | (4.3) %       |  |
| Adjusted EBITDA (non-GAAP)                   | \$ 41.1               |  | \$ 39.3       |  | \$ 69.1          |  | \$ 65.0       |  |
| Adjusted EBITDA margin (non-GAAP)            | 14.8 %                |  | 14.4 %        |  | 12.9 %           |  | 12.4 %        |  |

#### *Three Months Ended June 28, 2024 Compared to Prior Year*

Net sales increased \$4.3 million, or 1.6%, in the three months ended June 28, 2024 compared with the prior year period, which was negatively impacted by a \$3.8 million decrease from divesting a minor product line. Comparable sales growth for P&R was driven by approximately 3.3% organic growth in volumes, offset by 0.3% unfavorable foreign currency translation. Gross profit increased \$3.9 million and Gross profit margin increased by 60 basis points over the prior period due to operational efficiencies and improved mix due to the divestiture. Selling, general and administrative expense decreased slightly and decreased as a percentage of net sales due to a reduction of EU MDR spending. Operating income increased by \$6.9 million due to the aforementioned gross profit increase and reduction of EU MDR spending, as well as lower depreciation and amortization. Adjusted EBITDA and Adjusted EBITDA margin increased due to the aforementioned gross profit increase.

#### *Six Months Ended June 28, 2024 Compared to Prior Year*

Net sales increased \$12.6 million, or 2.4%, compared with the prior year period, which was negatively impacted by a \$3.2 million decrease from divesting a minor product line. Comparable sales growth for P&R was driven by approximately 3.1% organic growth in volumes, offset by 0.1% unfavorable foreign currency translation. Gross profit increased \$8.2 million and Gross profit margin increased by 30 basis points over the prior period due to operational efficiencies and improved mix due to the divestiture. Selling, general and administrative expense decreased primarily due to reduction of strategic transaction costs and EU MDR spending. Operating loss decreased due to the aforementioned Selling, general and administrative expense decrease and higher gross profit. Adjusted EBITDA and Adjusted EBITDA margin increased due to improved sales mix.

#### Reconstructive

We develop, manufacture, and market a wide variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity solutions that serve the orthopedic reconstructive joint implant market. Our products are primarily used by surgeons for surgical procedures.

The following table summarizes the selected financial results for our Reconstructive segment:

|  | Three Months Ended    |  |               |  | Six Months Ended |  |               |  |
|--|-----------------------|--|---------------|--|------------------|--|---------------|--|
|  | June 28, 2024         |  | June 30, 2023 |  | June 28, 2024    |  | June 30, 2023 |  |
|  | (Dollars in millions) |  |               |  |                  |  |               |  |
| Net sales                                    | \$ 247.4              |  | \$ 155.0      |  | \$ 504.7         |  | \$ 310.4      |  |
| Gross profit                                 | \$ 142.7              |  | \$ 106.1      |  | \$ 309.3         |  | \$ 214.2      |  |
| Gross profit margin                          | 57.7 %                |  | 68.5 %        |  | 61.3 %           |  | 69.0 %        |  |
| Selling, general and administrative expenses | \$ 154.4              |  | \$ 95.5       |  | \$ 304.6         |  | \$ 190.5      |  |
| Research and development expense             | \$ 14.2               |  | \$ 10.0       |  | \$ 28.8          |  | \$ 19.7       |  |
| Amortization of acquired intangibles         | \$ 18.0               |  | \$ 8.9        |  | \$ 35.7          |  | \$ 17.6       |  |
| Restructuring and other charges              | \$ 2.8                |  | \$ 1.8        |  | \$ 8.0           |  | \$ 3.3        |  |
| Operating loss (GAAP)                        | \$ (46.8)             |  | \$ (10.1)     |  | \$ (67.8)        |  | \$ (16.9)     |  |
| Operating loss margin (GAAP)                 | (18.9) %              |  | (6.5) %       |  | (13.4) %         |  | (5.4) %       |  |
| Adjusted EBITDA (non-GAAP)                   | \$ 49.1               |  | \$ 26.4       |  | \$ 104.4         |  | \$ 57.1       |  |
| Adjusted EBITDA margin (non-GAAP)            | 19.8 %                |  | 17.0 %        |  | 20.7 %           |  | 18.4 %        |  |

#### Three Months Ended June 28, 2024 Compared to Prior Year

Net sales increased by \$92.4 million, or 59.6%, in the three months ended June 28, 2024, of which \$90.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a \$2.2 million decrease from the discontinuance of certain non-core product lines. Comparable sales growth for Recon was driven by approximately 7.1% increases in volume and market share gains, offset by unfavorable foreign currency translation of 0.5%. Gross profit increased over the same period, primarily due to higher net sales due to the Lima Acquisition, improved operating cost leverage, offset by an increase of \$23.9 million in inventory fair value step-up amortization charges. Gross profit margin decreased primarily due to increased inventory fair value step-up amortization charges and product mix. Selling, general and administrative expense increased by \$58.9 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, and increases in existing business investments to support growth. Research and development expense increased compared to the prior year period due to the Lima Acquisition and increased spending within other recently acquired businesses in our Recon segment, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due to a \$17.1 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage.

#### Six Months Ended June 28, 2024 Compared to Prior Year

Net sales increased by \$194.2 million, or 62.6%, of which \$183.7 million was attributable to the Lima and the Novastep acquisitions. Recon sales were negatively impacted by a \$4.6 million decrease from the discontinuance of certain non-core product lines. Comparable sales growth for Recon was driven by approximately 7.0% increases in volume and market share gains and favorable currency translation of 0.4%. Gross profit increased \$95.0 million in the six months ended June 28, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, improved operating leverage, offset by an increase of \$28.8 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by \$114.1 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, and increases in existing business investments to support growth. Research and development expense increased compared to the prior year period due to the Lima Acquisition and increased spending within other recently acquired businesses in our Recon segment, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due to a \$32.4 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage.

## Liquidity and Capital Resources

### Overview

We finance our long-term capital and working capital requirements through a combination of cash flows from operating activities, various borrowings, and the issuances of equity. We expect that our primary ongoing requirements for cash will be for working capital, funding of acquisitions, capital expenditures, restructuring and other non-routine costs, and interest and principal repayments on our debt. We believe we could raise additional funds in the form of debt or equity if it were determined to be appropriate for strategic acquisitions or other corporate purposes. We believe that our sources of liquidity are adequate to fund our operations for the next twelve months.

### Equity Capital

In 2018, our Board of Directors authorized the repurchase of our common stock from time-to-time on the open market or in privately negotiated transactions. No stock repurchases have been made under this plan since the third quarter of 2018. As of June 28, 2024, the remaining stock repurchase authorization provided by our Board of Directors was \$100 million. The timing, amount, and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors. There is no term associated with the remaining repurchase authorization.

### Term Loan and Revolving Credit Facility

Our credit agreement (the "Enovis Credit Agreement") initially consisted of a \$900 million revolving credit facility (the "Revolver") with an April 4, 2027 maturity date and a term loan with an initial aggregate principal amount of \$450 million which was fully extinguished during the first quarter of 2023. The Revolver contains a \$50 million swing line loan sub-facility. Certain U.S. subsidiaries of the Company guarantee the obligations under the Enovis Credit Agreement. As of June 28, 2024, there was \$385 million available on the Revolver.

The Enovis Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments, or pay dividends. In addition, the Enovis Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum senior secured leverage ratio of not more than 3.75:1.00 and thereafter, stepping down to 3.50:1.00 for the fiscal quarter ending June 30, 2024 and thereafter, and (ii) a minimum interest coverage ratio of 3.00:1.00. The Enovis Credit Agreement contains various events of default (including failure to comply with the covenants under the Enovis Credit Agreement and related agreements) and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Revolver.

In connection with the Lima Acquisition, on October 23, 2023 we entered into an amendment to the Enovis Credit Agreement (the "Amendment"). The Amendment provides for a new term loan commitment in the aggregate amount of \$400 million. The term loan facility extended to the Company under the Amendment was funded on January 3, 2024, the date the Lima Acquisition was consummated. The term loan requires quarterly principal repayments at 1.25% of the initial aggregate principal amount, which is \$5 million each quarter, and matures on April 4, 2027 (the "2024 Term Loan").

Pursuant to the Amendment, effective as of the date of consummation of the Lima Acquisition, (i) all facilities under the Enovis Credit Agreement (including the 2024 Term Loan Facility) became secured by certain personal property of the Company and certain of its subsidiaries, subject to limitations and exclusions; (ii) the financial covenant under the Enovis Credit Agreement were adjusted to a new senior secured leverage ratio; (iii) certain changes to the negative covenants became effective (including restrictions on repayments of junior financing and amendments to junior financing documents); and (iv) certain additional changes were implemented (including the removal of the guaranty fallaway provision).

### Convertible Notes and Capped Calls

In connection with the signing of the definitive stock purchase agreement for the Lima Acquisition, we entered into several financing agreements in October 2023. On October 24, 2023, we issued \$460 million aggregate principal amount of senior unsecured convertible notes in a private placement pursuant to Rule 144A (the "2028 Notes"). The 2028 Notes have an interest

rate of 3.875%, payable semiannually in arrears on April 15 and October 15 of each year, beginning April 15, 2024. The 2028 Notes will mature on October 15, 2028 unless earlier repurchased, redeemed, or converted.

We also entered into privately negotiated capped call transactions with certain of the initial purchasers of the 2028 Notes. The capped call transactions are intended generally to mitigate potential dilution to our common stock upon conversion of any 2028 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2028 Notes, as the case may be, with such reduction and/or offset subject to a cap.

#### *Other Indebtedness*

In addition, we are party to overdraft facilities with a borrowing capacity of \$30.0 million. Total letters of credit and surety bonds of \$34.1 million were outstanding as of June 28, 2024.

#### *Cash Flows*

As of June 28, 2024, we had \$43.4 million of Cash, cash equivalents and restricted cash, a decrease of \$1.4 million from the balance as of December 31, 2023 of \$44.8 million. The following table summarizes the change in cash, cash equivalents and restricted cash during the periods indicated:

|   | <b>Six Months Ended</b>      |                      |
|---|------------------------------|----------------------|
|   | <b>June 28, 2024</b>         | <b>June 30, 2023</b> |
|   | <b>(Dollars in millions)</b> |                      |
| <b>Net cash provided by (used in) operating activities</b>        | \$ (28.4)                    | \$ 35.6              |
| Purchases of property, plant and equipment and intangibles        | (76.3)                       | (67.2)               |
| Payments for acquisitions, net of cash received, and investments  | (758.2)                      | (98.7)               |
| Payment for settlement of derivatives                             | (4.6)                        | —                    |
| <b>Net cash used in investing activities</b>                      | (839.2)                      | (166.0)              |
| Net borrowings of debt  | 878.5                        | 139.0                |
| Other financing   | (11.5)                       | (0.3)                |
| <b>Net cash provided by financing activities</b>                  | 867.0                        | 138.7                |
| Effect of foreign exchange rates on Cash and cash equivalents     | (0.9)                        | (0.1)                |
| Increase (decrease) in Cash, cash equivalents and restricted cash | \$ (1.4)                     | \$ 8.2               |

Cash flows from operating activities can fluctuate significantly from period-to-period due to changes in working capital and the timing of payments for items such as restructuring and strategic transaction costs. Cash flows from operating activities decreased \$64.0 million year-over-year. This decrease includes a higher investment in working capital of \$1.5 million, higher strategic transaction costs of \$26.5 million, higher restructuring payments of \$5.1 million and an increased cash paid for interest of \$23.2 million.

Cash flows used in investing activities during the six months ended June 28, 2024 were \$839.2 million compared to \$166.0 million in the prior year period due to higher investments in the current year driven by the Lima Acquisition for \$758.6 million, net of cash received. Cash flows used in investing activities during the six months ended June 30, 2023 included the acquisition of Novastep for \$96.9 million, net of cash received.

Cash flows provided by financing activities during the six months ended June 28, 2024 include \$878.5 million of net debt borrowings primarily used for the Lima Acquisition, capital expenditures and operations. Cash flows provided by financing activities for the six months ended June 30, 2023 include net debt borrowings of \$139.0 million primarily used for the acquisition of Novastep and capital expenditures.

#### **Critical Accounting Policies and Estimates**

The methods, estimates and judgments that we use in applying our critical accounting policies have a significant impact on our results of operations and financial position. We evaluate our estimates and judgments on an ongoing basis. Our estimates are based upon our historical experience, our evaluation of business and macroeconomic trends and information from other outside sources, as appropriate. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what our management anticipates, and different assumptions or estimates about the future could have a material impact on our results of operations and financial position.

There have been no significant additions or changes to the methods, estimates and judgments included in "Item 7A. Management's Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies" in our 2023 Form 10-K.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to market risk from changes in short-term interest rates, foreign currency exchange rates and commodity prices that could impact our results of operations and financial condition. We address our exposure to these risks through our normal operating and financing activities. We do not enter into derivative contracts for speculative purposes.

#### *Interest Rate Risk*

We are subject to exposure from changes in short-term interest rates related to interest payments on our borrowing arrangements. A significant amount of our borrowings as of June 28, 2024 are variable-rate facilities based on the Secured Overnight Financing Rate (SOFR). In order to mitigate our interest rate risk, we may enter into interest rate swap or collar agreements. A hypothetical increase in interest rates of 1% during the three and six months ended June 28, 2024 would have increased Interest expense for our variable rate-based debt under the Enovis Credit Agreement by approximately \$2.2 million and \$4.4 million, respectively.

#### *Exchange Rate Risk*

We are exposed to movements in the exchange rates of various currencies against the U.S. Dollar and against the currencies of other countries in which we manufacture and sell products and services. During the three and six months ended June 28, 2024, approximately 41% and 42% of our sales, respectively, were derived from operations outside the United States. We have manufacturing operations in certain foreign countries including Mexico, Switzerland, Italy, Germany, Tunisia, and China. Sales are more highly weighted toward the U.S. Dollar and Euro than other currencies. We also have significant contractual obligations in U.S. Dollars that are met with cash flows in other currencies as well as U.S. Dollars. To better match revenue and expense, as well as cash needs from contractual liabilities, we may enter into currency swaps and forward contracts.

We also face exchange rate risk from our investments in subsidiaries owned and operated in foreign countries. Our cross-currency swap agreements hedge our net investment in our Swiss Franc-denominated subsidiaries against adverse movements in exchange rates between the U.S. Dollar and the Swiss Franc. These swap agreements are designated and qualify as net investment hedges of our Swiss Franc net asset position. The effect of a change in currency exchange rates on our investment in Swiss Franc subsidiaries, offset by the unrealized gain or loss on the cross-currency swap investment hedges, is reflected in the Accumulated other comprehensive loss component of Equity.

We also face exchange rate risk from intercompany transactions between affiliates. Although we use the U.S. Dollar as our functional currency for reporting purposes, we have manufacturing sites throughout the world, and a substantial portion of our costs are incurred and sales are generated in foreign currencies. Costs incurred and sales recorded by subsidiaries operating outside of the United States are translated into U.S. Dollars using exchange rates effective during the respective period. As a result, we are exposed to movements in the exchange rates of various currencies against the U.S. Dollar. Similarly, tax costs may increase or decrease as local currencies strengthen or weaken against the U.S. Dollar.

#### *Commodity Price Risk*

We are exposed to changes in the prices of raw materials used in our production processes. In order to manage commodity price risk, we periodically enter into fixed price contracts directly with suppliers.

See Note 11, "Financial Instruments and Fair Value Measurements" in our Notes to Condensed Consolidated Financial Statements included in this Form 10-Q for additional information regarding our derivative instruments.

#### **Item 4. Controls and Procedures**

##### **Evaluation of Disclosure Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act, as of June 28, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Form 10-Q, our disclosure controls and procedures were effective in providing reasonable assurance that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

##### **Changes in Internal Control over Financial Reporting**

The Company completed the Lima Acquisition on January 3, 2024. Management considers this transaction to be material to the Company's consolidated financial statements and believes that the internal controls and procedures of Lima have a material effect on the Company's internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of Lima into our internal controls over financial reporting and extending our compliance program under the Sarbanes-Oxley Act of 2002 to include Lima. The Company will report on its assessment of the consolidated operations within the time period provided by the Exchange Act and the applicable SEC rules and regulations concerning business combinations.

Other than the Lima Acquisition noted above, there have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f)) identified in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **PART II - OTHER INFORMATION**

### **Item 1. Legal Proceedings**

Discussion of legal proceedings is incorporated by reference to Note 12, "Commitments and Contingencies," in the Notes to Condensed Consolidated Financial Statements included in Part I. Item 1. "Financial Statements" of this Form 10-Q.

### **Item 1A. Risk Factors**

An investment in our common stock involves a high degree of risk. You should carefully consider the risks set forth in "Part I. Item 1A. Risk Factors" of our 2023 Form 10-K and the other information set forth in this Form 10-Q, and the additional information in the other reports we file with the SEC before making an investment decision. If any of the risks contained in those reports actually occur, our business, results of operation, financial condition, and liquidity could be harmed, the value of our securities could decline, and you could lose all or part of your investment. There have been no material changes in the risk factors set forth in "Part I. Item 1A. Risk Factors" in our 2023 Form 10-K.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

During the six months ended June 28, 2024, none of our directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement as defined in Item 408 of Regulation S-K, except as noted below.

On June 3, 2024, Matthew L. Trerotola, the Company's Chief Executive Officer and Chair of the Company's Board of Directors, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) covering the sale of up to 182,572 shares of Company common stock upon the exercise of outstanding Company stock option awards, initially granted on February 25, 2019, through February 24, 2026, the expiration date of such awards.

## Item 6. Exhibits

| <u>Exhibit No.</u>        | <u>Exhibit Description</u>   |
|---------------------------|--|
| <a href="#">3.01.1*</a>   | Amended and Restated Certificate of Incorporation.   |
| <a href="#">3.01.2**</a>  | Certificate of Amendment to Amended and Restated Certificate of Incorporation  |
| <a href="#">3.01.3***</a> | Certificate of Amendment to Amended and Restated Certificate of Incorporation  |
| <a href="#">3.02****</a>  | Amended and Restated Bylaws of Enovis Corporation.   |
| <a href="#">10.1*****</a> | Second Amendment to Enovis Corporation 2020 Omnibus Incentive Plan   |
| <a href="#">21.1</a>      | Subsidiaries of the Registrant   |
| <a href="#">31.01</a>     | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| <a href="#">31.02</a>     | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| <a href="#">32.01</a>     | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                    |
| <a href="#">32.02</a>     | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                    |
| 101.INS                   | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.               |
| 101.SCH                   | Inline XBRL Taxonomy Extension Schema Document.  |
| 101.CAL                   | Inline XBRL Extension Calculation Linkbase Document.   |
| 101.DEF                   | Inline XBRL Taxonomy Extension Definition Linkbase Document.   |
| 101.LAB                   | Inline XBRL Taxonomy Extension Label Linkbase Document.  |
| 101.PRE                   | Inline XBRL Taxonomy Extension Presentation Linkbase Document.   |
| 104                       | Cover Page Interactive Data File - The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 28, 2024 is formatted in Inline XBRL (included as Exhibit 101). |
| *                         | Incorporated by reference to Exhibit 3.01 to Enovis (formerly Colfax) Corporation's Form 8-K (File No. 001-34045) as filed with the SEC on January 30, 2012.                         |
| **                        | Incorporated by reference to Exhibit 3.1 to Enovis Corporation's Form 8-K (File No. 001-34045) as filed with the SEC on April 8, 2022.   |
| ***                       | Incorporated by reference to Exhibit 3.1 to Enovis Corporation's Form 8-K (File No. 001-34045) as filed with the SEC on May 22, 2024.  |
| ****                      | Incorporated by reference to Exhibit 3.1 to Enovis Corporation's Form 8-K (File No. 001-34045) as filed with the SEC on December 15, 2022.   |
| *****                     | Incorporated by reference to Exhibit 10.1 to Enovis Corporation's Form 8-K (File No. 001-34045) as filed with the SEC on May 22, 2024.   |

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Registrant: Enovis Corporation

By:

|                                 |   |                |
|---------------------------------|---|----------------|
| <u>/s/ Matthew L. Trerotola</u> | Chief Executive Officer and Director                    |                |
| Matthew L. Trerotola            | (Principal Executive Officer)                           | August 7, 2024 |
| <u>/s/ Phillip B. Berry</u>     | Senior Vice President and Chief Financial Officer       |                |
| Phillip B. Berry                | (Principal Financial Officer)                           | August 7, 2024 |
| <u>/s/ John Kleckner</u>        | Vice President, Controller and Chief Accounting Officer |                |
| John Kleckner                   | (Principal Accounting Officer)                          | August 7, 2024 |

Exhibit 21.1

Enovis Corporation  
Subsidiaries of the Registrant

| Entity Name                                 | Domestic Jurisdiction | Country        |
|---|-----------------------|----------------|
| 360 Hip Systems Pty Limited                 | Australia             | Australia      |
| 360 Knee Systems (NZ) Limited               | New Zealand           | New Zealand    |
| 360 Knee Systems Pty Ltd                    | Australia             | Australia      |
| 360 Med Care Pty Ltd                        | Australia             | Australia      |
| Athena Finance Limited                      | Barbados              | Barbados       |
| Cefar-Compex Medical AB                     | Sweden                | Sweden         |
| Chattanooga Europe, B.V.                    | Belgium               | Belgium        |
| Colfax (Wuxi) Pump Company Limited          | China                 | China          |
| Colfax Group GmbH                           | Germany               | Germany        |
| DJ Orthopedics de Mexico, S.A. de C.V.      | Mexico                | Mexico         |
| DJ Orthopedics Services, SA de CV           | Mexico                | Mexico         |
| DJO Asia-Pacific Ltd.                       | Hong Kong             | Hong Kong      |
| DJO Benelux B.V.                            | Belgium               | Belgium        |
| DJO BRASIL LTDA.                            | Brazil                | Brazil         |
| DJO Canada Inc.                             | Ontario               | Canada         |
| DJO Consumer, LLC                           | Delaware              | United States  |
| DJO FINANCE LLC                             | Delaware              | United States  |
| DJO France S.A.S.                           | France                | France         |
| DJO Global India Healthcare Private Limited | India                 | India          |
| DJO Global Pty Ltd                          | Australia             | Australia      |
| DJO Global Switzerland SARL                 | Switzerland           | Switzerland    |
| DJO Global, Inc.                            | Delaware              | United States  |
| DJO Iberica Productos Ortopedicos S.L.      | Spain                 | Spain          |
| DJO Italia SRL                              | Italy                 | Italy          |
| DJO Medical Device Trading (Shanghai) Ltd.  | China                 | China          |
| DJO Nordic Aktiebolag                       | Sweden                | Sweden         |
| DJO Tunisie SARL                            | Tunisia               | Tunisia        |
| DJO UK Ltd.                                 | England and Wales     | United Kingdom |
| DJO, LLC                                    | Delaware              | United States  |
| Empi, Inc.                                  | Minnesota             | United States  |
| Encore Medical GP, LLC                      | Nevada                | United States  |
| Encore Medical Partners, LLC                | Nevada                | United States  |
| Encore Medical, L.P.                        | Delaware              | United States  |
| ENOVIS ATHENA GMBH                          | Switzerland           | Switzerland    |
| Enovis Ireland Limited                      | Dublin                | Ireland        |
| Enovis Japan Co., Ltd.                      | Japan                 | Japan          |
| ENOVIS SERVICES, UNIPESSOAL LDA             | Lisbon                | Portugal       |
| Enovis South Africa (Pty) Ltd.              | South Africa          | South Africa   |
| Insight Medical Systems, Inc.               | Delaware              | United States  |
| KICO Knee Innovation Company Pty Limited    | Australia             | Australia      |
| Lima Austria GmbH                           | Austria               | Austria        |
| Lima Belgium Bvba                           | Belgium               | Belgium        |
| LimaCorporate SpA                           | Italy                 | Italy          |
| Lima CZ s.r.o.                              | Czech Republic        | Czech Republic |
| Lima Denmark Aps                            | Denmark               | Denmark        |
| Lima Deutschland GmbH                       | Germany               | Germany        |
| Lima do Brasil Ltda                         | Brazil                | Brazil         |
| Lima France SaS                             | France                | France         |

|  |                    |                    |
|--|--------------------|--------------------|
| Lima Implantes Portugal S.U. LDA       | Portugal           | Portugal           |
| Lima Implantes SL                      | Spain              | Spain              |
| Lima Korea Co., Ltd                    | Korea, republic of | Korea, republic of |
| Lima Netherlands BV                    | Netherlands        | Netherlands        |
| Lima Ortopedija I implantati, d.o.o.   | Croatia            | Croatia            |
| Lima Orthopaedics Australia Pty Ltd    | Australia          | Australia          |
| Lima Orthopaedics New Zealand Pty Ltd  | New Zealand        | New Zealand        |
| Lima Orthopaedics South Africa Pty Ltd | South Africa       | South Africa       |
| Lima Orthopaedics UK Ltd               | United Kingdom     | United Kingdom     |
| Lima Polska SP Zoo                     | Poland             | Poland             |
| Lima SK S.r.o.                         | Slovakia           | Slovakia           |
| Lima Sweden S.r.o.                     | Sweden             | Sweden             |
| Lima Switzerland SA                    | Switzerland        | Switzerland        |
| Lima USA Inc.                          | Indiana            | United States      |
| Lima SM S.p.A.                         | San Marino         | San Marino         |
| Lima (Beijing) Medical Devices Co.     | China              | China              |
| Lima Orthopaedics Canada Inc.          | Canada             | Canada             |
| Litecure Asia Limited                  | Hong Kong          | Hong Kong          |
| LiteCure LLC                           | Delaware           | United States      |
| Litecure, LLC (Shanghai)               | China              | China              |
| LT Technology Ltd                      | China              | China              |
| Mathys (Schweiz) GmbH                  | Switzerland        | Switzerland        |
| Mathys AG Bettlach                     | Switzerland        | Switzerland        |
| Mathys KK                              | Japan              | Japan              |
| Mathys Ltd.                            | New Zealand        | New Zealand        |
| Mathys Orthopaedics Belux NV           | Belgium            | Belgium            |
| Mathys Orthopaedics BV                 | Netherlands        | Netherlands        |
| Mathys Orthopaedics Limited            | England and Wales  | United Kingdom     |
| Mathys Orthopaedics Pty Limited        | Australia          | Australia          |
| Mathys Orthopaedie GmbH                | Germany            | Germany            |
| Mathys Orthopaedie GmbH                | Austria            | Austria            |
| Mathys Orthopedie SAS                  | France             | France             |
| Mathys Ortopedia Srl                   | Italy              | Italy              |
| MEDSHAPE, INC.                         | Delaware           | United States      |
| Mo Milling Pty Ltd                     | Australia          | Australia          |
| Motion Parent, Inc.                    | Delaware           | United States      |
| MT Central Finance SARL                | Switzerland        | Switzerland        |
| NOVASTEP INC.                          | Delaware           | United States      |
| NOVASTEP SAS                           | France             | France             |
| Ormed GmbH                             | Germany            | Germany            |
| Ortho Pros Express, Inc.               | North Carolina     | United States      |
| Orthomed Medizintechnik GmbH           | Austria            | Austria            |
| PRECISION AI PTY LTD                   | Queensland         | Australia          |
| Quantum Ops, Inc.                      | Delaware           | United States      |
| Rikco International, LLC               | Wisconsin          | United States      |
| Speetec Implantate GmbH                | Germany            | Germany            |
| Surgi-Care, Inc.                       | Massachusetts      | United States      |
| Trilliant Surgical, LLC                | Texas              | United States      |



**CERTIFICATIONS**

I, Matthew L. Trerotola, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 7, 2024

/s/ Matthew L. Trerotola

---

**Matthew L. Trerotola**  
**Chair of the Board, Chief Executive Officer and Director**  
**(Principal Executive Officer)**

## CERTIFICATIONS

I, Phillip B. Berry, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 7, 2024

/s/ Phillip B. Berry

---

Phillip B. Berry  
 Senior Vice President and  
 Chief Financial Officer  
 (Principal Financial Officer)

**Certification Pursuant to 18 U.S.C. Section 1350  
(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)**

I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

1. the quarterly report on Form 10-Q of the Company for the period ended June 28, 2024 (the "Report"), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 7, 2024

*/s/ Matthew L. Trerotola*

---

**Matthew L. Trerotola**  
**Chair of the Board, Chief Executive Officer and Director**  
**(Principal Executive Officer)**

**Certification Pursuant to 18 U.S.C. Section 1350  
(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)**

I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

1. the quarterly report on Form 10-Q of the Company for the period ended June 28, 2024 (the "Report"), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 7, 2024

/s/ Phillip B. Berry

---

**Phillip B. Berry**  
Senior Vice President and  
Chief Financial Officer  
(Principal Financial Officer)